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The aspartyl protease human immunodeficiency virus type 1 (HIV-1) is a 99-amino acid-long 
homodimer responsible for processing the Gag and Gag-Pol polyproteins into functional constituent 
proteins necessary for development of infectious HIV particles.  Of global infections recorded, 
subSaharan African region is represented by 56 % where nearly 25 million people are living with HIV.  
South Africa has been shown to carry the heaviest HIV burden in sub-Saharan Africa where the HIV-1 
subtype C (C-SA) is the prominent strain.  Most of the HIV-1 scientific research has been done 
specifically for subtype B and this has been highlighted by the weaker binding affinity displayed by the 
South African HIV-1 subtype C for most of the clinically approved protease inhibitors when compared 
to the HIV-1 subtype B protease.    
The two flaps of the HIV-1 PR are very essential in functioning of the enzyme as their conformations 
control entry of the substrate into the catalytic site of the enzyme and also to release product.  It is very 
important to explore and understand the dynamics of these flaps in binding of different inhibitors with 
different binding affinities.  In addition, studies have highlighted the focus on inhibiting the cleaving 
function of HIV-1 PR with protease inhibitors (PIs) by competing with the natural substrate for the 
enzyme’s active or catalytic site and thus rendering its ineffective.  It has been shown that in addition 
to the active site, more regions of the enzyme can be possible targets for inhibition process by 
developing drugs that can hinder the opening of the flaps or disrupt the stability of the dimer interface.    
This study involved the use of computational techniques to explore the major contributing factors other 
than interactions with the binding site, in binding affinity of FDA approved second generation PIs 
complexed to HIV-1 C-SA PR.  In pursuance of this objective, molecular dynamics 
simulations, binding-free energy calculations and dynamic analyses were utilized. Several 
distances, different angles between certain residues were all taken into consideration  
Our findings do show that apart from binding free-energy calculations, not one single factor 
but several factors contribute to the binding affinity of protease inhibitors.  It is clear from these 
results that in the development of new HIV-1 drugs, more emphasis should be made in the 
iii  
  
design of drugs with, not only better binding in the active site but also with better interaction 
with other regions of the enzyme.  Another interesting emphasis drawn from this study is that 
there is still need for drug development targeting HIV-1 PR C-SA as the currently available 
drugs were modelled around the inhibition of HIV-1 subtype B.    
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CHAPTER ONE  
1. INTRODUCTION  
1.1 Background  
Since its discovery over three decades ago, when initial reports of the United Center for 
Diseases Control (CDC) were made 1, Acquired Immunodeficiency Syndrome (AIDS) is 
still regarded as the most devastating disease outbreak to date 2.  Many studies on the 
Human immunodeficiency virus (HIV) have been performed over the last few decades, as  
it is the causative agent for AIDS 3-5.  This has led to epidemic proportions in various parts 
of the world, whereby more than 36 million people were living with HIV in 2016, while  
over a million deaths have been recorded as a result of the disease 6, 7.   The progression of 
HIV infection to AIDS is the leading factor to the extreme suppression of the immune 
system in infected humans.  Of global infections recorded 8, east and southern-African 
regions  represent over 52 % of all HIV infections and nearly 19.5 million people are living 
with HIV.  In 2016 7, new HIV infections within the east and southern-African region 
displayed a 29 % decline from 1.1 million to approximately 790 000 infections per year.  
Within the continent of Africa, South Africa has been shown to be at the epicentre of the 
epidemic 9 as it counts for over 7 million individuals who are infected with HIV and 110 
000 deaths resulting from AIDS-related illnesses 7.  
Historically, long-term illness, and ultimately death were strongly associated with AIDS in 
the early discovery of this epidemic.  However, morbidity and mortality due to AIDS have 
shown to significantly decline to a manageable condition 10 and this is attributed to the 
introduction and use of the highly effective combination therapy, Highly Active 
Antiretroviral Therapy (HAART) 11 from the late 1990s 12.  Dramatic improvements were 
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achieved through the introduction of this therapy for HIV infected people, and also 
immunological as well as virological response to treatment was experienced by the majority 
of infected individuals 13.    
1.2 HIV (HIV-1 & HIV-2)   
Different strains of HIV may be carried by an infected individual in their body.  There are 
two main types of the virus: HIV-1 and HIV-2 and a further classification into groups and 
subtypes exist.  The isolation of HIV-1 was achieved by R.C. Gallo and L. Montagnier in 
1983 and this was followed by reports of another type; HIV-2 4.  HIV-1, the most common 
type found worldwide, is believed to have originated from the simian immunodefiency virus 
of chimpanzees (SIVcpz) 4, 14 whereas HIV-2, mainly found in Western parts of Africa and 
some regions in India and some in Europe is believed to genetically related to sooty 
mangabey virus (SIVsmm) 15.  New HIV-1 infections have declined by approximately 33% 
between the period of 2005 to 2013 16.  However, it is worth mentioning that the incidence 
of HIV-1 is still very high despite the decline in new infections 16.   
Despite many similarities that can be identified between HIV-1 and HIV-2, they can, 
however, be clearly distinguished from each other.  For example, a region which 
encompasses the core of mature HIV-1 virions has shown to be more electron-lucent when 
compared to the one observed in HIV-2 17.  The transmission of HIV-1 by sexual contact is 
more efficient than that of HIV-2 18.  Reduced pathogenicity of HIV-2 in comparison to 
HIV-1 as well as enhanced immune control of HIV-2 infection and consistent lower viral 
loads in the plasma of HIV-2 are also other major differences.  When these differences are 
looked into, they can provide necessary insights into the evolution, tropism and 
pathogenesis of the virus 19.  Despite having considerable phenotypic and sequence 
differences, HIV-1 and HIV-2 are morphologically quite similar 19, 20.  Basic free 
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arrangement, intracellular replicate pathways and modes of transmission are some of the 
similarities shared by HIV-1 and HIV-2 21.    
Group M (main), group O (outlier), group N (non-M/ non-O) and group P 22 are major 
phylogenetic groups by which HIV-1 variants are classified 22-26.  Group M is further 
subdivided into 10 phylogenetic subtypes (A to K) and this group constitutes the majority 
of HIV-1 infections worldwide.  Within group M, the average intersubtype genetic 
variability is 15 % for the gag gene and 25 % for the env gene 22, 25.  Recent studies on HIV1 
recorded that subtypes A, B and C, are the most prevalent genetic forms of HIV-1 
worldwide, whereby subtype C accounts for approximately 50 % of all HIV-1 infections 
on a global scale 9.  Countries in central and eastern African regions such as Uganda, Kenya,  
Rwanda, Tanzania and those countries in Eastern Europe are mostly affected by the subtype 
A virus, which is found to be predominant in these parts 27-29.   
1.3 HIV-1 virus infection –life cycle  
HIV is an enveloped, single-stranded RNA retrovirus and is classified as falling within the 
lentivirus subfamily of retroviruses 2, 30 and they’re known for their ability to 
reversetranscribe a genome of a 9,2 kb single-stranded RNA into a linear orientated double 
stranded DNA by viral transcriptase 2, 4.  Morphologically HIV-mature virions are known 
to possess a diameter of 100-120 nm and a lipid-bilayer membrane surrounds the viral 
particle (Figure 1).  The outer layer of the virus, the viral envelope (Env), acts as the outer 
shell of the virus and is the only surface protein.  Situated on the HIV-1 envelope are two 
molecules, glycoprotein (gp120) situated on the surface and the transmembrane protein  
(gp41) and the presence of these leads to the formation of spikes on the virion’s surface 31. 
There are three major genes carried by HIV-1; (gag, pol and env) and these form  




Figure 1. Schematic diagram of HIV virus.  Reprinted from Open Access literature33.  
Copyright under Creative Commons Attribution-Share Alike 3.0  
  
The immune system is damaged when the HIV virus attacks the white blood cells (i.e. T-helper 
cells/ CD4+ cells).  The role that CD4+ cells play in the well-functioning of the immune system 
and its T4 lymphocytes is vital.  In order for the HIV virus to achieve growth and 
reproducibility, it needs to develop new copies of itself and thus damaging and weakening the 
immune system 34.  This process takes place by a three-phased mechanism initiated by the direct 
viral killing of infected cells 34, 35. This is followed by increased rates of apoptosis found in 
infected cells and lastly, the ultimate killing of infected T-helper cells by CD8 cytotoxic 
lymphocytes which have the ability to detect infected cells 36.  The continuous development of 
T-helper cells is termed the HIV life cycle 35 and the stages of how the life cycle of HIV occurs 
will be discussed next.    
1. Binding and Fusion: The life cycle of HIV is initiated by the binding of the viral 
surface protein Envelope (Env) 37, 38.  This attachment of the virus is made possible 
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by the presence of the spikes (gp41 and gp120) situated on the surface of the virus 
particle (Figure 1) 39.  These proteins bind or stick to the CD4 receptor as well as the 
two-main chemokine co-receptors, either CCR5 or CXCR4 40-42.  After viral binding 
to the host cell, the envelope consisting of gp120 and gp41 heterodimers undergoes  
an irreversible conformational change 31, 43.  The initiated conformational change 
leads to fusion of the viral envelope and the CD4+ cell membrane which ultimately 
leads to the infection of a CD4+ cell 13, 31, 37, 41, 44.  Once the cell membrane of the virus 
has fused with that of the host cell, it leads to effective infection, whereby the genetic 
material ribonucleic acid (RNA), is introduced into the host cell 40.  
2. Reverse Transcription: The single-stranded RNA of the virus is then converted to a 
double-stranded DNA when it is inside the host cell by the enzyme referred to as  
reverse transcriptase in the cytoplasm of the host cell 40, 45.  This step is susceptible to 
a number of mutations as several errors are reported to occur during the replication 
process 46.    
3. Integration: Once the double-stranded DNA has been introduced into the host cell’s 
nucleus via reverse transcriptase, it then integrates into a chromosome of the host cell.  
The integrase enzyme is responsible for this step and this leads to a provirus being 
formed, which is basically an integrated HIV DNA 46.  This provirus can exist in an 
inactive form for several years whereby very few copies of HIV are released 47.  The 
compounds that are responsible for hindering this process are termed integrase 
inhibitors.  
4. Transcription and translation: Once the virus has been integrated and the host cell has 
been triggered to be active, the proviral DNA is transcribed into messenger RNA 
(mRNA).  In the nucleus of the host cell, production of full-length RNA molecules 
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takes place 15, 46. The newly transcribed mRNA is then translated by host machinery 
into viral polyprotein precursors consisting of the env, gag and gag-pol 46.  
5. Assembly and Budding: After viral polypeptide precursors have been translated, they 
assemble in the cell membrane into immature (non-infectious) HIV particles 48, 49.  
The strands of messenger RNA contain various copies of HIV genetic material and a 
new virus particle is assembled which results in the formation of a curvature 48.  This 
curvature leads to the formation of a bud and in the process of budding, part of the 
host cell’s exterior envelope gets taken by the new virus (via endocytosis) and the 
new virus releases HIV protease enzymes, whose main objective is to cleave the long  
chains of HIV polyproteins to create mature viral proteins 2, 50, 51.  The newly 
assembled immature (non-infectious) viral particles gather to form mature 
(infectious) HIV particles and they bud from the host cell to be released for infection  
of other host cells 46, 52.  The exterior envelope of the new viral particle consists of 
HIV glycoproteins that are essential for interaction with the CD4 and co-receptors of 
the host cells.  At this stage, the new virus cell selects two copies of genomic RNA 




Figure 2: Schematic diagram of HIV virus life cycle.  Reprinted from Open Access literature33. 
Copyright under Creative Commons Attribution-Share Alike 3.0  
  
1.4 Different enzymes (Integrase, transcriptase, protease)   
Proteins  
The identification of the HIV retrovirus and understanding of HIV genome has led researchers 
around the world to focus largely on three major distinct proteins; integrase, reverse 
transcriptase, and a protease 56.  Development of inhibitors targeting various steps that 





1.5 HIV- Inhibitors (RTIs, PIs, IIs, FIs)/ HAART/ side effects  
  
Since the outbreak of acquired immunodeficiency syndrome (AIDS) epidemic, over three 
decades ago when its causative agent was first isolated, the understanding and accumulated 
knowledge about the virus has led to tremendous efforts being made in transforming the HIV1 
disease, which was initially regarded as a highly fatal infection, into a treatable chronic 
infection 12, 57.  Application of antiretroviral therapies has increased in possibility of survival 
and resulted in a decline in death rates of HIV patients57.  It is understood that theoretically, the 
different steps of HIV life cycle are identified as targets for the development of antiretroviral 
therapy.  However, the current highly active antiretroviral therapy (HAART) 10, 58, consists of 
at least three major groups of inhibitors drawn from four classes which are used in the clinical 
practice and they are inhibitors of the reverse transcriptase (nucleoside/ nucleotide, NRTIs, and 
non-nucleoside, NNRTIs), integrase inhibitors (IIs), protease inhibitors (PIs) 12, 59 and the recent 
first fusion inhibitor (FI).  The use of HAART to most patients has shown to result in an 
increase in CD4+ T cell counts, reduction in morbidity and mortality 60, 61.   
While major strides have been made concerning the use and application of HAART, it is well 
understood that its success is limited by numerous severe side effects associated with the 
treatment (Table 1) 60, 62, 63.  Insulin resistance hyperlipidemia, subcutaneous fat wasting, 
lipodystrophy, hypertoxicity, hyperglycemia, diarrhoea etc. 57, 62, 64  are some of recorded side 
effects associated with long-term use of the antiretroviral therapy.  Besides the recorded side 
effects, there are also numerous drug resistant strains which have developed 50, 65.  








Table 1: Chronology of events that took place in the development of HIV-1 therapy. 57  
 
Year  HIV therapy   
1981  Recognition of AIDS 4  
1983  Isolation of HIV-1 66  
1987  Introduction of first FDA-approved therapy,  
1991  Approval of most NRTIs by FDA 57  
1995 Understanding of dynamics on HIV virus 68  
1995/1996  Introduction of the first protease inhibitors  
1996 FDA approval of the first NNRTI  
2003  Introduction of fusion inhibitors 71  
The first discovery of a therapy targeting HIV was that of a nucleoside analogue called 
zidovune, designed to inhibit HIV-1 reverse transcriptase and it received FDA approval in 1987 
57, 67.  Inhibitors of this type, nucleoside (NRTIs), interfere with the replication of HIV-1 by 
blocking the reverse transcriptase, which is used in conversion of the viral RNA into DNA 57,  
67.  This results in the slowing down of the replication process and in the case of HIV-1 proviral 
DNA being terminated 67, 72.  Between the year 1991 and 1995, the period where AIDS was 
being regarded as the number one killer in the world, additional NRTIs were introduced.  The 
rest of current NRTIs were also introduced after that (Table 1).  
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a class of drugs which are 
structurally diverse and bind directly and non-competitively to the enzyme reverse  
transcriptase.  It is interesting to note that despite the chemical differences in their structures, 
NNRTIs tend to bind at a region distant from the normal binding site of the substrate.  The 
binding of NNRTIs induces conformational change in the substrate-binding site of reverse 
transcriptase and leading to reduced DNA polymerase activity and thus inhibiting the activity 
of RT 57.  Unlike nucleoside analogues, these inhibitors do not exhibit activity against RT of 
HIV-2.    
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When scientists gained a better understanding of the virus, they recognized other drug targets 
in addition to reverse transcriptase.  Drug development progress was made when a new class 
of drugs, enfurvitide (T-20), was introduced and was approved in March 2003 by the FDA57, 58.   
Enfurvitide is currently still the only fusion inhibitor approved by the FDA 10, 57.  Structurally, 
it is a linear, 36-amino-acid synthetic peptide which was designed to inhibit HIV-1 entry into 
host cells 10.  The fusion portion of the HIV-1 envelope glycoprotein in gp41 is the main target 
of these drugs as they prevent the full conformational changes of the viral envelope necessary 
for the fusion of viral membrane and that of the host cell 57, 73.  As is the case for many drugs, 
enfurvitide also has limitations and these include its requirement to be administered by 
subcutaneous injection for human administration 74.  
Major successes were made in the discovery and development of other HIV targets and these 
included those of the viral protease.  This enzyme is essential and plays a major role in ensuring 
proper virion maturation and assembly in the post-translational process 75-77.  HIV protease has 
been a prime target for drug design since the late 1980’s when the first crystal structure of HIV1 
protease was reported 78, 79. This is because of its indispensable role in viral maturation which  
ultimately leads to final morphological rearrangement 2, 80, 81.  The introduction of inhibitors 
results in production of immature virus particles and thus ensuring that virus replication is 
hindered while reducing the spread of viral infection in susceptible host cells 2, 76, 82.  It was the 
discovery of the crystal structure of the HIV-1 protease that made it possible for the design of 
antiviral protease inhibitors to be achieved 76.  The design of most protease inhibitors mimics 
the transition state of the actual substrate of the enzyme 83-85.    
Ideally protease inhibitors should possess good oral bioavailability in humans, potency against 
HIV clinical isolates, and specificity for HIV-1 protease 57.  Potency of inhibitors is highly 
affected by their affinity for the protease, their penetration ability to cells and most importantly, 
how strongly they are bound to the protein.    
11  
  
Saquinavir (SQV), popularly known by its brand name Invirase is a peptidomimetric  
hydroxyethylamine and was developed by F. Hoffman La Roche Ltd 75, 86, 87.  It was marketed 
in 1995 and it was the first HIV protease inhibitor used to treat AIDS patients to be approved 
by FDA.    
Ritonavir (RTV), also known as Norvir in the market, is a peptidomimetric HIV protease  
inhibitor and was developed by Abbott Laboratories that was approved in 1996 83, 87.  It was 
designed on the basis that it would have a “perfect” fit in the C2-symmetry of the protease 
binding site 65.  The isopropyl thiazoyl P3 group in ritonavir is found to be much longer than 
the one found in other HIV protease inhibitors 88.  Initially, there were challenges associated 
with RTV, for example, the developers of the drug started with the compounds that exhibited 
activity for the virus but showed poor bioavailability.  This then led to some improvements 
being to the structures of the compounds as pyridal groups were added in place of terminal 
phenyl residues, which were removed leading to increased water solubility.  These  
improvements resulted in RTV being the final product 75, 83, 88.  In spite of the gastrointestinal 
side effects associated with it, RTV is still regarded as a strong inhibitor of the cytochrome P450 
enzyme mediated metabolism75 as it also prevents the metabolism of other protease inhibitors  
83.  
Merck & Co, Inc., developed indinavir (IDV) and it was given the brand name Crixivan when 
it was approved in 1996 52.  It is a peptidomimetric hydroxyethylene HIV protease inhibitor and 
it was designed on the basis of molecular modelling and the X-ray crystal structure of an earlier 
drug lead compound bound to the enzyme 89.  An advantage of this inhibitor is the fact that it 
is effective for both HIV-1 and HIV-2 83.  A relative short half-life of circulating indinavir and 
low solubility are some of its main drawbacks 90.    
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Nelfinavir (NFV), also termed Viracept, was the first example of a nonpeptidic, potent HIV 
protease inhibitor 91.  It was developed by Agouron Pharmaceuticals in USA and was approved 
in 1997 83.  This orally bioavailable agent was designed with the help of an iterative protein 
cocrystal structure analysis of peptidic inhibitors 75.  The structure of nelfinavir has the same 
DIQ group as saquinavir in one terminus while on the other it possess a 2-methyl-
3hydroxybenzamide group 56.    
Vertex Pharmaceuticals Incorporated developed Amprenavir (APV) (Agenerase) and it was 
approved by the FDA in 1999 (Figure 3) 87.  APV is an N,N-disubstituted amino sulfonamide 
nonpeptide HIV protease inhibitor 92.  APV contains a similar core to that of SQV but the 
functional groups on both ends are somewhat different.  There is a tetrahydrofuran carbamate 
group on one end while an isobutylphenyl sulphonamide is located on another end with an 
added amide 75.  There are fewer chiral centers present in APV than in other HIV protease 
inhibitors.  In 2004, APV was withdrawn from the market as its prodrug, fosamprenavir, proved 
to be superior in many aspects.  Fosamprenavir (FPV) is the phosphate ester prodrug of APV 
and was approved for use in 2003.  This inhibitor also possesses better solubility and 







Figure 3. Structures of HIV PR inhibitors and the natural substrate (1KJH). 
 
Lopinavir (LPV) was developed by Abbott Laboratories as ABT-378 with the intention to 
ensure that the activity against Val 82 mutant HIV protease is retained 84.  It received approval 
by the FDA as a coformulation with ritonavir under the brand name Kaletra on 15 September 
2000 96.  It was found that there is a substantial increase in LPV drug exposure as a result of 
coformulation with RTV by inhibiting cytochrome P450 isoenzyme 3A4 84, 96. 
An aza-dipeptide analog, Atazanavir (ATV), (brand name: Reyataz) was developed by 
BristolMyers Squibb Co in 2003 and it has potent anti-HIV activity 83, 87.  ATV has a unique 
structural characteristic as it has a large phenylpyridyl P1 group which is situated asymmetrical 
relative to its benzyl P1’ group and it was designed to fit the C2-symmetry of the HIV protease 
binding site 94.  What is interesting about this inhibitor is that it requires an acidic environment 
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for adequate absorption 95.  Previous reports have shown that fewer side effects are associated 
with ATV than with other HIV protease inhibitors 96, 97.    
Tipranavir (TPV) (brand name: Aptivus) was developed in Germany by Boehringer Ingelheim 
GmbH and was approved in 2005 83.  It was developed from a nonpeptidic coumarin template 
and is a sulfonamide which has 5,6-dihydro-4-hydroxy-2-pyrone 98, 99.  TPV uses the lactone 
oxygen atom situated on the dihydropyrone ring for direct interaction with the Ile50 residues 
found in the flap region that ensures stability of the complex 83.  The structural orientation of 
tipranavir in the active site results in seven direct hydrogen bonds with residues of the protease 
that are conserved and as such, water-mediated hydrogen bonds are fewer when compared to 
other PIs 100.  Intracranial haemorrhage and decompensated hepatitis are two adverse effects 
associated with TPV.  
Known as Prezista in the market, darunavir (DRV) was approved in 2009 by the FDA 87. It is 
a nonpeptidic analogue of amprenavir.  There are structural and chemical similarities between 
amprenavir and its analogue, darunavir but they are distinguishable from each other by the 
number of tetrahydrofuran (THF) groups, APV has one and DRV has two of these groups 83.  
Another factor that distinguishes these two inhibitors is the fact that darunavir has a higher 
binding affinity to PR 101, 102.  The increased binding affinity of darunavir is believed to be linked 
to the bis-THF moiety at P’ 103 which leads to strong hydrogen bonds being formed with the  
backbone atoms found at residue D29 and D30 100, 104.  Minor toxicity was observed for 
darunavir in some of the infected patients.  Diarrhoea, rash, nausea and nasopharyngitis are 
some of the recorded side effects associated with the drug 105.    
It is of critical importance for inhibitors to have a high binding affinity for the wild-type HIV  
protease and possess resilience when mutations occur 106-108.  Despite the side effects that have 
been observed and reported, it can be stated that HAART has brought dramatic changes in 
ensuring that morbidity and mortality rates of people infected with HIV are significantly 
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reduced 57.  Reports now have shown that drug design research on HIV/AIDS is aimed at 
discovering anti-HIV drugs that will possess low toxicity, reduced resistance, less side effects, 
improved potency and better oral bioavailability 32, 109.  Requirement for anti-HIV drugs that 
will act on alternative target areas is of importance.  Numerous new anti-retrovirals, which 
could be potential anti-HIV drugs are currently still under investigation 110-113.  They range from 
(L-731, 988 and S-1360) 110, 111, 114, gp120-CD4 interaction inhibitors (BMS-378806, FP21399, 
PRO542, zintevir, BMS806 and PRO140) 113, 115,116 inhibitors of CXCR4 coreceptor  
(ALX40-4C; T22, T134, T140; AMD3100; AMD3465) and those of CCR5 coreceptor 
(AK602, E913, NSC-651016, TAK-220, TAK-779, SCH-C, SCH-D) 61, 117 fusion inhibitors 
(T1249) 112, 118-120.  In addition to these, many more anti-retrovirals are also still being  
investigated 112, 121, 122.    
1.6 Flap dynamics of HIV-PR  
1.6.1 The structural information of HIV-1 protease  
HIV-1 protease falls under a class of aspartic proteases which is composed of two flexible 
βhairpin flaps that are necessary in the control of substrate entry to the binding cavity (Figure 
4) 77, 109, 123.  The flexibility of the flaps is said to be necessary for facilitating ligand entry, 
binding and also product release 75, 124.  The homodimeric HIV-PR normally contains 99 amino 
acid residues in each monomer and each monomer consists of one of two catalytic aspartyl 
residues.   
Like most other aspartic proteases, HIV-1 PR contains the catalytic triad (Asp25-Thr26-Gly27)  
at position 25, 26 and 27 respectively 77, 124, 125.  The aspartyl groups found in proteases are found 
to exist in opposite states of protonation and this is to achieve the catalytic competent form of 
monoprotonation 32, 77.  The flap tips, residues 46-54 are hydrophobic despite having a high 
degree of solvent exposure 126.    
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The HIV-1 protease consists of three main regions which are briefly discussed next.   
• Active site region (core region)   
The core region contains the conserved catalytic triad, Asp25-Thr26-Gly27 covered by the 
βhairpin flaps which are also important as they participate in substrate and inhibitor binding 
and  
product release 2, 75, 77.  The inhibitor interacts with the active site of the protease by forming 
hydrogen bonds and it is this network of bonds which ensures stability of the conserved core 
region.  
• Terminal region (dimerization interface)  
The terminal region (residues 1-5 and 95-99) is made up of antiparallel β sheets that result from  
the four termini in the dimer interface located at residues 1-5 and 95-99 51, 127.  This particular 
region is regarded as being very important as it ensures formation of dimer and also 
stabilization of the active protease enzyme 128.    
• The flap domain  
The flap domain consists of residues 32-63 129 which are found to contain β-hairpin 
structures (residues 43–58) and they play a significant role in ligand binding interactions.  
The flap domain has glycine-rich ends, allowing it to be more mobile and flexible.  The 
flaps can adopt many conformational states and they are said to be in a ‘handedness’ 
orientation in relation to each other 130.  The stability and movement of the flap domain is 
highly affected by the hinge region which is defined as the comprising residues 35–42 and 
57–61 131.    
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1.6.2 The stability of HIV protease  
The stability of the protease is highly affected by pH and concentration 132, 133.  It is increased at 
higher pH values 132.  The presence of the inhibitor stabilizes the closed dimeric structure of the 
protease in a fashion that can be quantitatively described by a set of thermodynamic  
equations 134.    
1.6.3 HIV-1 substrate binding and protease catalytic mechanism  
Aspartic proteases, also known as acidic proteases, fall under the group of endopeptides 135.  
Their enzymatic ability is also highly affected by the mechanical fluctuation and 
conformational changes on the protein structure 136.  In order for the segments of the substrate/ 
inhibitor to access the active site, the flaps of the protease (residues 33–62) needs to open 126 
and for cleavage to occur the flaps need to close while the appropriate region of the substrate 
is in the active site.  The conformational changes that occur in the HIV-1 protease are highly 
influenced by the flexibility of the flaps and the increased flexibility may lead to drug resistance 
137.  This augmented movement is made possible by glycine rich ends of residues 46-56 




Figure 4: Ribbon representation of different flap handedness in HIV-1 protease. The 
handedness of (A) substrate-bound protease in closed form (e.g., 2BBB), (B) free protease in 
semi-open form (e.g., 1HHP). The difference in handedness between closed (C) and semi-open 
(D) flap conformation, with the flaps being highlighted by rotating the structures 90° 
horizontally behind the plane.  
The two aspartyl β-carboxyl groups situated at the active site of the protease activate the water 
molecule in between the two residues.  A side chain of another amino acid activates the 
nucleophile which is usually a hydroxyl group and the resulting nucleophilic atom then attacks 
the carbonyl of the scissile amide bond resulting in the formation of an ester or a thioester acyl 
intermediate 141.  The activated nucleophile affects the peptide in two ways: first, the carbonyl 
that is being attacked becomes a gemdiol and second, there is a hybridization change of the 
amide nitrogen from sp2 to sp3 142.  Eventually, hydrolysis of the acyl enzyme intermediate by 
the water molecule takes place and the resulting products are formed 2.  Various reports have 
indicated that a water molecule is located between the active site aspartates2.    
1.7 Background on relevant studies of HIV-1 PR   
1.7.1 Experimental studies   
There have been several experimental studies that reported on binding affinities of a number of 
FDA-approved drugs for HIV-1 protease.  Velazquez-Campoy et al. reported that subtype C 
HIV-1 protease displayed higher catalytic efficiency against two different substrates in 
comparison to A and B subtype proteases 143.  This was followed by another study where 
authors recorded that several protease inhibitors displayed lower binding affinities with factors 
from 2 to 7.5 against subtype A and B proteases exhibiting naturally occurring amino acid 
polymorphism144.  The authors highlighted the fact that the drug-resistant mutation is 
significantly impacted by the pre-existing lower affinity in subtype A and C proteases.  
A study exploring active site mutations in HIV-1 subtype C (C-SA) protease was reported.  
Their experimental work indicated that the mutations could not affect the catalytic activity of 
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the C-SA protease 9.  It was demonstrated that the binding affinities of protease inhibitors 
seemed to decrease as a result of the V82F and I84V double mutation in C-SA protease.  A 
study by our group reported binding free energies for nine clinically approved HIV protease 
inhibitors against the I36T↑T mutant (100 amino acids in the monomer).  This mutant displayed 
lower binding affinities and weaker inhibition when compared to the wild-type protease 145.  
Various experimental techniques have been applied to study the flap opening and closing 
mechanism as well as dynamics of the flaps covering the active site of the HIV-1 protease.  For 
many years, 15N nuclear magnetic resonance spectroscopy (NMR) relaxation methods have 
been widely employed to analyse inhibitor-HIV-1 protease interactions 138.   With the use of 
these experiments, Ishima et al.138 reported measurements of the transverse 1H 15N relaxation 
rates of backbone amides of HIV-1 in inhibitor-bound and unbound forms.  The β-sheet 
interface of the inhibitor-bound protease was found to have some fluctuation on the millisecond 
timescale compared to the microsecond timescale for the unbound protease and this implies 
that the β-sheet interface for the inhibitor-bound form was rigid 138.    
Several X-ray diffraction studies 79, 146, 147 on the free enzyme highlighted the fact that the flaps 
are loosely packed onto each other in their semi-open conformations.  Reports on the overall 
structure of the enzyme showing that the structure is less compact when compared to the crystal 
structure of the ligand bound protease have also been published 148, 149 .  In addition, other studies 
on the inhibitor-bound HIV-1 protease highlighted the fact that the β-hairpins at the flaps have 
a well-ordered orientation and tend to have interactions with most inhibitors 5.    
Galiano et al. 150 reported results from site-directed spin labelling (SDSL) double 
electronelectron resonance (DEER) studies of the conformations of the flaps of HIV-1.  Such 
results demonstrated that these employed techniques can distinguish conformations of the flaps 
in the free and inhibitor-enzyme complex forms.    
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Torbeev et al. 151 studied protein conformational dynamics in the mechanism of HIV-1 protease 
catalysis.  The authors used chemical synthesis as well as relatively advanced physical methods 
to perform thorough analysis of dynamics-function correlations for the HIV-1 protease 151, 152.  
Their results showed that the conformational isomerization in the flaps is correlated with 
structural reorganization of residues in the active site region.  They also concluded that this 
preorganization of the active site is the rate-limiting factor in catalysis 151.   
    
1.7.2 Computational studies   
In addition to various experimental studies being reported, a huge impact has been made by 
computational reports on binding affinities of various protease inhibitors.  A study by our group 
highlighted a comparative analysis of the binding affinities of nine FDA-approved drugs 
against subtype B as well as the South African subtype C 153.  From the MD study, it was 
observed that there was an increased flap movement for C-SA PR, which was suggested to be 
the reason for the weaker affinities.  Molecular dynamics simulations were carried out on the 
complexes to calculate the average binding free energies for each inhibitor using the molecular 
mechanics generalized Born surface area (MM-GBSA) method.  The binding affinities 
indicated that second generation FDA approved PIs (ATV, DRV, LPV and TPV) displayed a 
different activity pattern for C-SA protease compared to subtype B 154.    
A number of computational techniques have also been reported on the flap opening and closing 
mechanism of HIV protease 155-157.  A study reported by Collins et al. 158 investigated flap 
opening in HIV protease using activated molecular dynamics simulations in gas phase.  The 
authors used native (PDB: 3HVP) and MVT-101 bound conformations (PDB: 4HVP) of HIV 
protease, which differ in terms of handedness.  
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The curling of flap tips was proposed as a key conformational trigger for flap opening in HIVPR 
by Scott and Schiffer 126.  They highlighted an interesting phenomenon whereby the flap tip 
residues, Gly-Gly-Ile-Gly-Gly, curled back, thus burying several hydrophobic residues.  The 
conformational flexibility that was highlighted was in good qualitative agreement with reported 
NMR experiments 138, 139.  However, the flap opening observed in such early studies only 
occurred within the first few nanoseconds of the calculation.  This fact has been suggestive that  
improper equilibration had occurred  159.   
1.7.3 Proposed parameters to measure flap dynamics  
  
Various studies have reported on different parameters used to describe flap motion in aspartic 
proteases.  A molecular dynamics study by Karubiu et al. 160. reported different combined 
parameters that were proposed and applied to define the flap motion during the opening and 
closing in plasmepsin proteases 160.  The three combined parameters, the distance between the 
flap tip residues, d1, the dihedral angle, Ф, and the TriCα angles, θ2, were found to be the most 
appropriate in better defining the flap motion of plasmepsin (Plm) proteases.  
Another study also reported proposed parameters in defining flap opening and closing on Plm 
proteases 161.  The authors considered d1; Ф, and TriCα, θ1 as being prime parameters to 
appropriately define the extent of opening and closing of flap structures in apo plasmepsins 161.    
A comparative MD study of flap flexibility on beta-amyloid precursor protein cleavage enzyme 
1 (BACE1) and enzyme 2 (BACE2) explored different combined parameters to better describe 
flap flexibility 162.  The authors found that all four proposed parameters, d1, the dihedral angle, 
Ф, and TriCα angles, θ1 and θ2 seemed to appropriately define the twisting motion observed 
during opening and closing of flaps.    
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1.8 Computational background   
Several computational methods have occupied a significant space in the study of biochemistry 
and physics.  Most of computational methods have been used in the exploration of macroscopic 
and microscopic fluctuations that occur in biomolecular systems, ligand binding, and free  
energy surface 157, 163-167.  Several of these computational tools have been utilized to better 
understand the interaction of the substrate/ inhibitor in the active site region of the enzyme 
(HIV-1 protease).  There are two broad areas within computational chemistry devoted to the 
structure of molecules and their reactivity.  Two main methods constitute the area of 
computational chemistry; molecular mechanics and quantum mechanics whereby the former is 
based on the classical laws of physics to make predictions about structures and the properties  
of molecules 168-170.  The use of molecular mechanics (MM) is advantageous for very large 
systems such as enzymes.  This method of calculation is characterized by a particular force 
field with embedded parameters, whereby the electronic effects are implicitly included in the  
force field through parameterization168, 171.  Consideration of a solvent in MD simulations is 
vital as this ensures it eliminates artefacts due to a lack of solvent 172, 173.  
Quantum mechanics utilise the laws of quantum theory instead of classical physics to describe 
a chemical system 165, 174.  This branch of computational chemistry solves the Schrödinger 
equation to determine the energy and other properties of a chemical system or a molecule 175.  
MD simulations enable detailed information on the atom vibrations, movements, collisions, 
fluctuations and conformational changes to be obtained and this ultimately leads to studies on  
drug design and structure determination to be explored 176-178.  Normally the atoms of molecules 
are regarded as being in constant motion where they are heated to a specific temperature so as 
to overcome the potential energy barriers 172.    
23  
  
Explicit solvation includes the effect of water and uses hundreds or even thousands of discrete 
solvent molecules 173.  The large number of particle involved makes the explicit solvation 
calculations to converge only slowly 179.  This method is currently only practical for MM 
calculations.  Despite the fact that this method of simulation is widely used its high 
computational expense is its drawback 179.    
Implicit solvation is a model to approximate average effects of solvent by describing the 
interaction between the solvent and solute as a function of solute coordinates.180, 181 This allows 
for faster sampling of conformational space 182, 183.  A number of previous studies have  
compared explicit and implicit solvent systems and concluded the latter to be much faster 182- 
185.   
Calculating binding free energies 186, 187 is another important area that brings about a defining 
factor in studying interaction between ligands and enzymes.  Binding free energy allows 
prediction of the ability of particular substrate to associate with the receptor and therefore 
provides predictions about binding affinities of the substrate 188, 189.   
In this study, the binding affinities of various inhibitors ranging from the best, middle, weak, 
and weakest in terms of their binding energies obtained experimentally were studied to explore 
flap dynamics.    
1.9 Objectives of the present study  
This study forms part of a research project aimed at looking at how conformational flexibility 
of HIV PR, the key structural feature governing the binding mechanism of inhibitors, is affected 
by the strength of binding affinity.  The specific objectives of this study were:    
• To make necessary theoretical observations using molecular dynamics calculations as 
to which of the employed parameters best describe the flap dynamics of HIV-1 C-SA  
PR as some, flap tip distance for example, are affected by the curling of flap tip residues.    
24  
  
• To calculate the binding affinity of inhibitors for C-SA PR using MD and find the 
relationship between that and the influence of the respective inhibitors on flap  
flexibility.  
• To determine how binding affinities of the inhibitors correlate to the  
complimentary/punitive interactions between the inhibitor-enzyme.   
• To explore the impact of the dimerization interface on the stability of HIV-1 C-SA PR.   
    
1.10 Outline of this thesis  
This thesis consists of four chapters and they are presented as follows:  
Chapter 1 presents an in-depth exploration of the background information on the main subject 
of this study.  
Chapter 2 presents the first manuscript submitted for publication and it looks at the flap 
dynamics of HIV-1 C-SA PR in the bound and substrate-bound form.  
Chapter 3 presents a second manuscript which is prepared for submission.  This manuscript 
presents findings from a study on how dimerization inhibition affects the stability of HIV-1 
CSA PR.  
Chapter 4 provides a summarization, conclusion, and recommendations from the findings of 
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Abstract  
HIV-1 protease (HIV PR) is considered one of the most attractive targets for the treatment of  
HIV and the impact of flap dynamics of HIV PR on the binding affinities of protease inhibitors 
(PIs) is one of the crucial ongoing research field.  Recently, our research group evaluated the 
binding affinities of different FDA approved PIs against the South African HIV-1 subtype C 
(C-SA) protease (PR).  The CSA- HIV PR displayed weaker binding affinity for most of the 
clinical PIs compared to HIV-1 B subtype for West and Central Europe, the Americas. In the 
current work, the flap dynamics of four different systems of HIV-1 C-SA PR in complex with  
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FDA approved second generation PIs and its impact on binding was explored over the 
molecular dynamic trajectories.  It was observed that the interactions of the selected drugs with 
the binding site residues of the protease may not be the major contributor for affinity towards 
PIs.  Various post-MD analyses were performed, also entropic contribution, solvation free 
energy and hydrophobic core formation interactions were studied to assess how the flap 
dynamics of C-SA PR is affected by such factors.  From these contributions, large van der 
Waals interactions and low solvation free energies were found to be the major factors for the 
higher activity of ATV against C-SA HIV PR.  Furthermore, a comparatively stable 
hydrophobic core may be responsible for higher stability of the PR flaps of the ATV complex.  
The outcome of this study provides significant guidance to how the flap dynamics of C-SA PR 
is affected by various factors as a results of the binding affinity of various protease inhibitors. 
It can also leads to the design of potent inhibitors against C-SA HIV PR that apart from binding 
in the active site of PR can interacts with the flaps to prevent opening of the flaps resulting in 
inactivation of the protease.    
Keywords: HIV-1 protease (HIV PR); South African subtype C (C-SA HIV PR); Molecular 
dynamics (MD); Flap dynamics.  
2.1 Introduction  
Acquired Immunodeficiency Syndrome (AIDS) is regarded as one of the most devastating 
disease outbreaks to date (1-4).  Human Immunodeficiency Virus (HIV) is the causative agent 
for AIDS and approximately 36.7 million people were reported to be suffering from AIDS at 
the end of 2016 (4).  Sub-Saharan Africa faces the most devastating HIV and AIDS epidemic 
in the world.  Of global infections recorded, sub-Saharan African represents 56% with nearly 
25 million living with HIV.  In the year 2015, 960 000 new HIV infections were experienced 
by countries within the east and southern Africa regions and close to 470 000 deaths associated 
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with HIV and AIDS were recorded in the same year (5).  Within the continent of Africa, South 
Africa has been shown to be at the epicentre of the epidemic as an estimated 6.1 million people  
(12% of total population) are living with HIV (6).  Among different subtypes of HIV-1, subtype 
C (C-SA), is mostly prevalent in this region and this subtype accounts for approximately 50% 
of all HIV-1 infections globally (3).  C-SA protease has eight point mutations compared to 
subtype B and these are T12S, I15V, L19I, M36I, R41K, H69K, L89M, and I93L (7).  In 
subtype B, the hinge and cantilever regions (loops) slide over I15 and this interaction with the 
hydrophobic core allows anchoring of the flaps(7).  In C-SA protease the hydrophobic 
interactions are affected due to polymorphisms observed in I15V, L19I, M36I,H69K, L89M 
and I93L (7).    
The fulcrum, hinge and cantilever regions consist of six mutations (T12S, I15V, L19I, M36I, 
R41K and H69K) that distinguish C-SA from subtype B (3, 7).  The I15V is a part of the 
hydrophobic core and the L19I mutation is believed to contribute to the rearrangement of 
hydrophobic interactions in the hydrophobic core (7).  This core has 19 amino acid residues 
with hydrophobic side chains (5L, 11V, 13I, 15I, 22A, 24L, 33L, 36M, 38L, 62I, 64I, 66I, 75V, 
77V, 85I, 89L, 90L, 93I and 97L) found in each monomer of HIV-1 protease.  These amino 
acid residues exchange hydrophobic interactions which are essential to maintaining 
conformational flexibility of the proteases including flap dynamics (7, 8).  Furthermore, four 
of these residues are mutated in C-SA protease and these are I15V, M36I and L89M and I93L.  
In the C-SA HIV-1 protease, these polymorphisms lead to perturbed hydrophobic sliding that 
are likely to be one of the major reasons for drug resistance (7, 9).  
The HIV-1 protease has been a prime target for drug design because of its indispensable role 
in viral maturation, which ultimately leads to final morphological rearrangement (1, 10, 11).  
HIV-1 protease is generally a homodimer with two identical monomers (chain A and chain B) 
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each consisting of 99 amino acids (12).  However, our group recently reported 100 and 101 
amino acid mutant variants of C-SA protease that demonstrated little difference in catalytic 
activity with respect to the natural substrate (2, 13).  The first mutant has one extra amino acid  
(I36T↑T) and the second mutant has two additional amino acids (L38L↑N↑L) in each monomer 
(13).  Limited data from another study, reported by our group (14) demonstrated that FDA 
approved protease inhibitors exhibit reduced activities against subtype C because of residue 
polymorphism.    
We have previously reported the theoretical binding affinity of nine FDA approved protease 
inhibitors (PIs) [amprenavir (APV), atazanavir (ATV), darunavir (DRV), indinavir (INV), 
lopinavir (LPV), nelfinavir (NFV), ritonavir (RTV), saquanavir (SQV) and tipranavir (TPV)] 
with subtype B and C-SA on the basis of 2 ns molecular dynamics simulations (14).  In addition, 
we separately reported the theoretical binding affinities of these FDA approved drugs against 
I36T↑T mutation of subtype C-SA (2).  Recently, our group determined the experimental 
binding affinities of these nine FDA approved drugs against C-SA PR and the mutant (I36T↑T) 
(15).  The binding affinity data (15) (Table 1) indicated that second generation FDA approved 
PIs (ATV, DRV, LPV and TPV, Figure 1) display a different activity patterns for C-SA 
protease compared to subtype B.  Interestingly, four second generation PIs (ATV, DRV, LPV 
and TPV) showed considerable variations of binding affinity against C-SA protease.  
Therefore, the proportion of open conformation of C-SA protease is higher than that of subtype 
B.    
Previously it was reported that overall conformational stability of the C-SA protease is slightly 
reduced as compared to the subtype B (differential scanning calorimetry experiments) (16).  By 
measuring the magnitude of forces responsible for stabilising the native structure of proteins 
(17, 18), the authors demonstrated that differences in structural stability could have an influence 
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in binding affinity of inhibitors.  This is as a result of the conformational change that is 
associated with inhibitor or substrate binding (18).  Furthermore, experimental results (7) 
revealed that the reduced drug susceptibility of C-SA protease may be attributed to altered 
dynamics around the flaps (hydrophobic core) of the C-SA protease as well as reduced 
probability of Glu35-Arg57 salt bridge formation.  Both of these factors are assumed to have a 
strong correlation with the region that allows for flap opening and closure (7).  Salt bridge 
formation also affects the conformational stability of the protease.  Therefore, apart from 
binding energy calculations and analyses, it is imperative to understand the flap dynamics and 
its determinants (such as hydrophobic sliding mechanism and salt bridge formation) in detail 
to explain the structural requirements of inhibitors against C-SA protease.    
Herein, molecular dynamic (MD) simulations, binding free energy calculations and dynamic 
analyses were combined to understand how the flap dynamics of C-SA protease is affected by 
binding energy patterns observed in different second-generation FDA approved drugs.  It is 
expected that this work serves as guidance in ensuring that the new potential drugs to be 
developed do not only have a “strong” binding in the active site but also have interactions with  






Figure 1. Chemical structures of four of the FDA approved second generation PIs.  
  
  
Various metrics have been proposed and employed to explore different flap conformational 
states of HIV-1 PR.  The distance between α-carbons of Ile50 and Ile50ʹ residues is the most 
commonly used metric parameter (19, 20).  Others that were employed are the distance between 
the α-carbons of Lys55 and Lys55’ (21, 22) as well as between those from α-carbons of Ile50 
and Asp25 or Ile149 and Asp124 (22, 23).  In order to determine the curling behaviour of the 
flap tip residues, the TriCα angle between Gly49-Ile50-Gly51 for each monomer is measured 
(23, 24).  The flaps of the HIV-1 PR have been shown to be asymmetric in their dynamic 
motions (25) and the tips of the flaps have been known to display twisting (26).  As such, the 
dihedral angle (Ф) amongst residues ILE50-ASP25-ILE149-ASP124 was taken into account in 
understanding the flap twisting of HIV-1 PR (27).  
2.2 Computational Methods  
2.2.1 Preparation of inhibitors/enzyme complex  
The crystal structures of the wild-type subtype B HIV-1 protease complexed with four FDA 
approved drugs were obtained from the Protein Data Bank (PDB).  The PDB entries are as 
follows: 3U71 (apo/free)(28), 3EL1 (ATV)(29), 4DQB (DRV)(9), 1MUI (LPV)(30) and 2O4P 
(TPV)(31) while the PDB entry for the natural substrate is 1KJH.  The C-SA/inhibitor 
complexes were prepared as described previously (2).    
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2.2.2 Setting up the system for Molecular Dynamics (MD) simulations  
Prior to molecular dynamics simulations, the protonation states of residues of HIV-1 C-SA 
were assigned at pH=7.0 using the PropKa server (32, 33).  The ff99SB (34) and the general 
AMBER force field (GAFF) (35) were used to describe the inhibitor–protein and inhibitor– 
solvent interactions, respectively.  The ligands were parameterized with Leap (35) implemented 
in Amber 14, using the general AMBERforce field (GAFF) (35) in Antechamber.  MD 
simulations were performed using Amber 14 with the ff99SB (34) force field with the TIP3P 
(36) explicit water in a cubic box with 8 Å distance around the complex.  The positive charge 
of the complexes were neutralized with chloride ions.  Partial Mesh Ewald (PME) (37) method 
was used to consider long range electrostatic forces (cutoff 12 Å).  Additionally, the SHAKE 
algorithm (38) was used to constrain all bonds to hydrogen atoms.  To reduce the overlapping 
atom interactions of initially prepared solvated complexes, energy minimization was performed 
in two stages.  In the first stage only ions and water molecules were relaxed by 2000 step 
minimization process (1000 steps of steepest decent minimization followed by 1000 of 
conjugated gradient) using a restrained force of 500 kcal/mol on the solute.  For the second 
stage of minimization, the whole system was relaxed by 5000 step minimization process (2500 
steps of steepest decent minimization followed by 2500 of conjugated gradient).  The 
minimized systems were gradually heated up from 0 to 300 K with a weak harmonic restraint 
of 10 kcal/mol to keep the solute fixed for 200 ps.  Subsequently, the 2 ns constant pressure 
equilibration at 300 K were performed.  Lastly, 60 ns MD simulations without restriction were 
run at a constant temperature of 300 K and constant pressure at 1 atm.    
In order to validate the results, a set of three different simulations were performed by using 
different starting structures obtained from 20, 40 and 60 ns snapshots. These structures were 
retrived from the original 60 ns MD simulation.    
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2.2.3 Post-dynamics analysis  
After the completion of each MD simulation, the analyses for the root mean square deviation 
(RMSD), root mean square fluctuatuion (RMSF), hydrogen bond analyses as well as distance 
and angle analyses were performed using PTRAJ and CPPTRAJ module (39) implemented in  
Amber 14 (Figures 2,3 and Tables 2, 3).  
2.2.4 Binding free energy calculations  
Molecular Mechanics/Generalized Born Surface Area (MM-GBSA) (40) binding free energies 
of inhibitors were calculated using MM-PBSA program in Amber 14.  For each complex, 400 
snapshots were taken from the last 2000 ps of the 60 ns MD trajectory with an interval of 5 ps.   
In this method the binding energy is represented as:  
∆𝐺 = ∆𝐸𝑒𝑙𝑒 + ∆𝐸𝑣𝑑𝑊 + ∆𝐺𝑝𝑜𝑙 + ∆𝐺𝑛𝑜𝑝𝑜𝑙 − 𝑇∆𝑆  
The first two terms ∆Eele and ∆EvdW are calculated by molecular mechanisms and represents 
the electrostatic and van der Waals interactions with the proteins in gas phase.  The polar 
solvation free energy ∆Gpol is calculated by using the MM-PBSA program (41) and it represents 
polar interactions with the solvent molecules.  The ∆Gnonpol signifies non-polar solvation free 
energy and is obtained from the equation ∆𝐺𝑛𝑜𝑛𝑝𝑜𝑙𝑎𝑟 = 𝛾𝑆𝐴𝑆𝐴 + 𝛽 (42).  The solvent accessible 
surface area (SASA), the surface tension proportionality constant (𝛾) and the free energy of 
nonpolar solvation of a point solute (𝛽), were set to 0.00542 kcal mol-1 Å-2 and 0 kcal mol-1, 
respectively (43).  The entropy contribution to the binding free energies were calculated using 
normal mode analysis (44-47) for the complexes from changes in the translational, rotational 
and vibrational entropy components (Table 1).  
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2.2.5 Per residue free energy decomposition analysis  
To evaluate the contributions of individual residues to the total binding free energies of the 
inhibitors/PR complexes were computed using the MM-GBSA per residue free energy 
decomposition method (48, 49) in Amber 14 (40).  All energy components including van der  
Waals, electrostatic, polar solvation and nonpolar solvation contributions were calculated using  
400 snapshots extracted from the last 2000 ps MD trajectories (Figure 5 and 6) of the 60 ns MD 
simulation.    
2.2.6 Principal component analysis (PCA)   
To understand conformational changes of the proteins, PCA analyses were performed using the 
PTRAJ (39) module of Amber 14.  Correlated and anti-correlated motions were studied using 
the dynamics cross-correlation calculations derived by dynamics trajectories.  The 
crosscorrelation coefficient (cij) for each pair of alpha carbon (Cα) atoms i and j were calculated 






                                                                                                      (1) 
The ∆rnis the displacement of the nthatom mean position.  The angle parentheses represent the 
time average over the entireity of each trajectory.  The collective motions were produced using 
the positional covariance matrix C based on the atomic coordinates and their corresponding 
eigenvectors.  The eigenvalues and eigenvectors stand for extent and direction of motions of 
atoms respectively (51).  The elements of the positional covariance matrix C were computed 
using the following equation(52):  
𝐶𝑖 =< (𝑞𝑖−< 𝑞𝑖 >)(𝑞𝑗−< 𝑞𝑗 >) > (𝑖, 𝑗 = 1,2, … ,3𝑁)          (2)  
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The Cartesian coordinate ∆qn stands for the nthCα atom, and N is the number of Cα atoms.  To 
remove all translational and rotational movements, the average is calculated after 
superimposition with a reference structure using a least-square fit procedure to extract the 
important motion from MD trajectories (53-55).  The matrix C is symmetric and is diagonalized 
by an orthogonal coordinate transformation matrix, which transforms the matrix C into a 
diagonal matrix of eigenvalues.  The eigenvectors corresponds to the direction of motion 
relative to cartesian coordinate of each atom and each eigenvector is related to an eigenvalue 
that describes the total mean-square fluctuation of the system along the corresponding 
eigenvector.  The porcupine plot of protein collective motions was created by the NMWiz tool 
in VMD (56) (Figure 7).    
2.3 Results and discussion  
2.3.1 MM-GBSA binding energy analyses   
To understand the major determinants for the binding affinity of the FDA-approved 
secondgeneration drugs, MM-GBSA binding free energy analyses were carried out for all four 
drug- 
PR complexes.  The calculated binding free energies [∆Gbind(T)] and their components (∆Evdw, 
∆Eelec, ∆Ggas, ∆Gpolar, ∆Gnonpolar, ∆Gsolvation, TΔS) were calculated by MM-GBSA (40) binding 









Table 1. Calculated binding free energies [∆Gbind(T)] and its components for the four second 
generation HIV-1 protease inhibitors and the natural substrate (NS) on C-SA PR. The 
experimental binding energies [∆Gbind(E)] (15) is also depicted. The energy components are in 
kcal/mol and entropy (-TΔS) in kcal/mol.  
Complexa  ∆Evdw  ∆Eelec  ∆Ggas  ∆Gpolar  ∆Gnonpolar  ∆Gsolvation  -TΔS  ∆H  ∆Gbind (T)  ∆Gbind (E)b  
NS  -89.08  -16.42  -105.05  47.40  -12.13  35.27  33.26  -70.23  -36.97   
ATV  -79.86  -7.75  -87.62  30.81  -10.00  20.80  30.42  -66.81  -36.39  
  
-14.35  
DRV  -65.91  -37.15  -103.06  53.46  -8.30  45.15  23.15  -57.92  -34.77  -13.81  
LPV  -76.37  -9.40  -85.77  27.83  -9.81  18.02  33.85  -67.74  -33.89  -13.24  
TPV  -60.78  -37.97  -98.75  57.79  -8.38  49.41  25.47  -49.34  -23.87  -13.19  
aThe complex systems are ranked in order of theoretical binding energies.  
bExperimental binding free energies for four inhibitors on C-SA PR reported by Maseko et al. (15).  
  
It is evident from Table 1 that the theoretical binding energies [∆Gbind(T)] of the compounds 
follow the same order as the experimental binding energies [∆Gbind(E)] reported by our 
group(15) which  reveal that the computational model is effective.  The purpose of the current 
work is not necessarily to compare the theoretical and experimental activities but to discover 
major determinants responsible for different experimental binding affinities. Determinants that 
will be explored are interatomic interaction occurring in HIV-1 PR complexed with inhibitors 
as well as distance analysis for the protease.  Additional parameters to study flap dynamics will 
also be explored.    
The results demonstrate that the natural substrate attained the highest theoretical binding energy 
when compared to the inhibitors.  The high van der Waals interaction observed -89.08 kcal/mol 
for the natural substrate is thought to be the major contributing factor towards the high binding 
affinity of the substrate.  Interestingly, ATV exhibited less electrostatic interactions (∆Eelec = -
7.75 kcal/mol) among other complexes.  However, it still exhibits strong inhibition with a 
∆Gbind(T) = -36.39 kcal/mol mainly due to high van der Waals (∆Evdw = -79.86 kcal/mol) 
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interactions as well as reduced polar (∆Gpolar = 30.81 kcal/mol) and higher non-polar (∆Gnonpolar 
= -10.00 kcal/mol) solvation energies.    
The TPV—PR complex, on the other hand, demonstrated relatively high electrostatic 
interactions (∆Eelec = -37.15 kcal/mol) among other inhibitors but its van der Waals interactions 
(∆Evdw = -60.78 kcal/mol) showed that TPV exhibited the weakest binding affinity compared 
to the other inhibitors.  Furthermore, this result can be attributed to an increased ∆Gpolar (=  
57.79 kcal/mol) that leads to a high cost of solvation energy (∆Gsolvation = 49.41 kcal/mol).  The 
DRV—PR complex demonstrated similar interactions to TPV—PR as exemplified by the 
reduced hydrophobic interaction energy (∆Evdw = -65.91 kcal/mol), increased electrostatic 
interaction energy (∆Eelec = -37.15 kcal/mol) as well as increased solvation free energy 
(∆Gsolvation = 45.15kcal/mol).  The similar interactions of these two inhibitors can be linked to 
their structural arrangement as they both contain a sulphonamide moiety, an extremely polar 
group. This clearly explains the high values of ∆Gpolar for both DRV and TPV and these 
inhibitors have to desolvate water around them in order to be accommodated in the active site, 
leading to paying a desolvation penalty (57) and hence the observed large values of ∆Gsolvation 
for both of these inhibitors.  
When comparing LVP—PR with the best inhibitor it can be seen that both demonstrate a similar 
pattern of interaction energies as exemplified by increased ∆Evdw (= -76.37 kcal/mol), reduced 
∆Eelec(= -9.40 kcal/mol) and reduced ∆Gsolvation (= 18.02 kcal/mol).  As far as the entropy of the 
systems are concerned, comparative increased entropy was observed for ATV and LPV 
complexes as compared to DRV and TPV complexes.    
    
2.3.2 Stability and flexibility of the HIV-1 PR complexes  
In order to explore the dynamic stability of the apo enzyme, natural substrate (NS) and the four  
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HIV-1 inhibitor complexes, root-mean-square deviation (RMSD) values of the Cα, C and N 
atoms were calculated and are presented in Figure 2A.  All these systems maintained RMSD 
values of less than 2.5 Å in the whole simulation run whereas all drug/PR complexes displayed 
better dynamic stability (RMSD < 2.0 Å) than the apo form which was able to attain an RMSD 
of above 2 Å at around 22 ps.  In addition, all these systems (Figure 2A) display an average 
RMSD values of less than 1.5 Å  including those presented in Figure S2 (Apo: 1.408 Å, NS: 
1.4436 Å, ATV: 0.944 Å, DRV: 1.173 Å, LPV: 1.378 Å, TPV: 0.838 Å).  Interestingly, among 
all the complexes, ATV—PR and TPV—PR revealed better dynamic stability as the RMSD of 
the two systems rarely crossed 1.200 Å during the entire run.  The RMSD analysis indicates 
that the fluctuations of the all systems from corresponding crystal structures are similar.  Three 
different MD simulations of ATV and DRV were carried out by varying initial atomic 
coordinates or initial atomic velocities. RMSD plots of these conformations showed that they 
displayed relatively similar stability (Figure S1).  
 
Figure 2. (A) Root Mean Square Deviation and (B) Root Mean Square Fluctuation for the 4 
systems over the 60 ns MD trajectory.  
 
To understand the residue fluctuations and flexibilities, the root mean square fluctuation 
(RMSF) plot was also analysed.  This plot (Figure 2B) indicates that the drug/PR complexes 
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experience much lower fluctuations for the most part of the simulation.  Due to the fact that the 
active site region is known to be rigid (58) our analysis for fluctuation focussed on the flap 
region.  The fluctuations of the drug/PR complexes are extensively reduced in the flap regions  
(residue 43-56 and residue 42’-55’).  Considering that flap dynamics is directly related to 
substrate stability in the HIV-1 protease (59), it may be assumed that binding of the drugs 
stabilizes the flap regions (retaining closed/semi-open conformation), although the extent of 
stabilization varies from compound to compound.  The flap opening takes place by concerted 
downward movements of fulcrum (residues 10-23), hinge (residues 35-42 and 57-61) and 
cantilever (residues 62-78) regions (60).  Simultaneously, these three important regions 
fulcrum, hinge and cantilever including the flap region were analysed from the RMSF plot 
(Table 2).  Higher stability of residues in these regions were obtained for all complexes in the 
decreasing order of TPV, ATV, DRV, LPV and NS with the apo enzyme having the least 
stability (Table S2-B).  The RMSF plot indicates that the overall fluctuations of these three 












Table 2. Average RMSFs observed in different regions of the apo, natural substrate and drugC-
SA protease complexes for the 60 ns MD simulation.    
Regionsa  Chain     Average RMSF (Å)   
Apo  NS  ATV  DRV  LPV  TPV  
Fulcrum   
A  0.883  0.7307  0.792  0.950  1.05  0.802  
 B  0.871  1.0895  0.702  1.026  0.921  0.685  
Hinge  
A  1.121  1.0242  0.93  0.923  1.035  0.769  
 B  1.214  1.0905  0.818  0.870  0.981  0.808  
Flap  
A  1.421  0.9552  0.737  0.771  0.884  0.639  
 B  1.896  0.9490  0.709  0.736  0.898  0.683  
Cantilever  
A  0.94  0.8286  0.694  0.847  1.026  0.616  
 B  0.807  0.8904  0.619  0.761  0.752  0.589  
a Fulcrum: residues 10-23), hinge: residues 35-42 and 57-61, Flap: residues 45-55 and cantilever: residues 62-78.  
  
Flap dynamics of HIV-1 PR is closely associated with the substrate binding and is therefore a 
crucial part of drug binding and effectiveness (61).  Analyses of the RMSF plots indicated that 
flap dynamics play an important role and can be used to determine the functionalities of the 
FDA approved second generation drugs in C-SA PR.  The movements of the flap region and 
other parts of the enzyme were further analysed by the principal component analyses (PCA) 
analysis in the latter part of the manuscript.  To obtain insight on the flap dynamics, some 
important distances (62, 63) and angle analyses (62, 63) were measured over the MD 




Figure 3. Distance and angle analyses for the elucidation of flap dynamics in C-SA PR for the  
60 ns MD simulations; (A) distance between flap tips (Ile50 and Ile50ʹ), (B) distance between 
active site residue and flap tip in chain A (Asp25-Ile50), (C) distance between active site 
residue and flap tip in chain B (Asp25ʹ -Ile50ʹ), (D) TriCα angle of chain A (Gly49-
Ile50Gly51), (E) TriCα angle of chain B (Gly49ʹ-Ile50 ʹ-Gly51ʹ), (F) dihedral angles of chain 




Initially the stability of the semi-open flap conformation was monitored by measuring the 
distance between Ile50 and Ile50ʹ, which are located on the tip of the flaps.  The flap tip distance 
between these two residues is one of the most frequently studied flap dynamics parameter in 
the HIV-1 protease (59, 64, 65).  It is clear from the plot in Figure 3A that the apo form displays 
prominent flexibility as the flap tip distance ranged from approximately 5 Å to close to 10 Å.  
The flap tip distance attained by the natural substrate complex ranged between 5.5 and 7.5 Å 
and this indicates that the presence of the substrate ensured that the flap tip residues are much 
more rigid.  It is observed that the drug  ATV complex  has a flap tip distance (Ile50 and Ile50ʹ) 
that moved within a shorter range compared to those of other drug complexes (Figure S3-A), 
whose flap tip distances displayed a periodic increase from closed (5-6 Å) to semi-open (9-10 
Å) form.    These figures demonstrate that complex formation significantly reduces fluctuations 
of the flap residues.  Such an observation is supported by experimental evidence (66) where it 
was reported that inhibitor binding induces a shift to the closed state in C-SA PR.  In the current 
analysis, ATV attained flap tip distance values of slightly less than 8 Å and DRV- and 
LPVcomplexes showed higher tendency to remain in semi-open conformation (Figure S3) 
while TPV displayed even smaller flap tip distances. Interestingly, all these drug complexes 
rarely achieved full closed conformations (5-6 Å) (61) which has been reported as an important 
characteristic of C-SA protease by experimental evidence (7, 66).  The drug complexes 
displayed a range flap-tip distance of 7-9 Å and did not achieve 5-6 Å attained by Apo as shown 
in Figure S3-A.    
The distance between Asp25 and Ile50 of a given subunit has already been introduced as 
another an important criterion in understanding flap dynamics (67).  A distance of more than 
15.8Å is considered to represent a semi-open conformation for the flap gate (68).  However, 
more importantly this parameter helps us to understand the volume of the active site (62).  The 
distances between Asp25 and Ile50 residues of chain A and chain B are presented in Figure 3B 
56  
  
and 3C, respectively.  Similar to the flap tip distance analyses, the apo form of the enzyme was 
found to cover a wide range of values (11-17.5 Å) for these parameters while the natural 
substrate displayed distances between approximately 12 to 16 Å.  The drug complexes, on the 
other hand, displayed narrow ranges for the corresponding distances.  In chain A (Asp25Ile50), 
the histogram plots for the ATV, DRV, LPV and TPV—PR complexes overlapped with each 
other with increasing peak values distributed at 12.7, 13.3, 13.7 and 13.8 Å, respectively 
(Figures 3B and C and Figure S3 B and C).  However, in chain B the distance between 
Asp25ʹIle50ʹ varied to a considerable extent from one complex to another.  The histogram peak 
of ATV—PR was located at 15.0 Å, which is around 2 Å longer than for DRV—PR, having 
histogram peak value found at 13.2 Å.  The Asp25ʹ-Ile50ʹ peaks for the LPV and TPV 
complexes are overlapped with larger peak values distributed at 12-12.2 Å.  These figures 
suggest that the ATV—PR has a considerably larger active site volume than other complexes 
(62).  On the other hand, the corresponding distances (Asp25ʹ -Ile50ʹ) for all complexes were 
shorter than this value for the apo form suggesting that binding of drugs stabilized the flap 
fluctuations to a considerable extent.  In chain B, the ATV complex showed comparatively 
longer distances between these two amino acids (Asp25ʹ and Ile50ʹ), and this clearly shows that 
the dynamic behaviour of the flaps is unsymmetrical as the ATV complex displayed mostly 
shorter distances.  The results also show that the apo form of HIV-1 PR displayed relative high 
symmetry as a similar pattern for the distances between the flap tip and active site residue on 
both chains was almost similar.    
Schiffer et al. (65) used the term flap curling of the TriCα angles of the residues in the flap tip 
or nearby region (Gly49-Ile50-Gly51) to investigate the open and closed conformations of flap 
dynamics.  The higher curling of the flap tips produces faster flap opening(68).  These results 
are presented in Figure 3 (D and E) while those that include DRV and LPV are in Figure S3 (D 
and E).  The ATV and DRV complexes reveal more flap curling in of flap tip residues justified 
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by lower TriCα angles in both chains (Chain A: Gly49-Ile50-Gly51, Chain B: Gly49ʹIle50ʹ-
Gly51ʹ) in Figure 3D and 3E as well as Figure S3, D and E.  The LPV—complex showed 
comparatively higher TriCα angles in both chains indicating the flap region of this complex 
appears to exhibit higher flexibility than other complexes (Figure S3D and E).  The TPV— 
complex displayed variable flap curling in two different chains.  It seems to suggest that TPV 
binding leads to anti-correlated movements in two different chains (Figure 3D and 3E).  In 
addition, it is interesting to note that for both D25-50 and the TriCα angle, the TPV complex 
seemed to reveal smaller distance and angle values in one similar monomer, respectively, and 
that is due to a very strong hydrogen bond network that is established by TPV in various 
fundamental regions of the protease.  For example, there is a strong hydrogen bond interaction 
between the backbone carbonyl oxygen of Gly48 and the hydrogen between the sulphonamide 
and the aromatic ring as can be seen in Figure S9.  The hydrogen bond network is also 
strengthened by the interaction of Gly27 carbonyl oxygen and the aromatic carbon found 
between the trifluoromethyl group and the pyridine nitrogen (Figure S9).   
To study such conformational changes, the dihedral angle, (Ф), was also calculated in the post 
MD analysis between the Cα atoms of the tip-catalytic dyad-hinge residues (Ile50-Asp25-Ile50ʹ  
-Asp25ʹ).  Evaluating the dihedral angle gave insight into the twisting motion of the Cα atoms 
between the- flap tip, active site and hinge residues in the flexible region.  It is evident that 
major twisting phenomenon did not occur for the ATV and DRV complexes (Figure S3F).  It 
is evident that a major twisting phenomenon did not occur in all systems as none of them had 
any shifting in angles from a positive to a negative side or from the positive side to the other 
side as this would have implied such a motion (69).  However, it is worth mentioning that the 
apo form displayed a wider range of dihedral angle compared to the natural substrate and 
inhibitor-bound complexes (Figure 3F).  Figure S3F does indicate that the two inhibitors with 
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lower binding affinities (LPV and TPV) seemed to have wider ranges for the dihedral angle 
compared to the two inhibitors with higher binding affinities (ATV and DRV).    
Overall, from all these distance and angle analyses, it may be inferred that the drug complexes 
achieve neither fully closed nor semi-open conformations.  They rather remain in close to 
semiopen states as observed earlier by Naicker et al.(7, 28).  The ATV complex showed a larger 
active site volume compared to other complexes.  Furthermore, the DRV—PR and LPV—PR 
complexes displayed longer flap-tip distances than other two drug complexes.  The TriCα 
analyses as well as dihedral angle analyses revealed that LPV (both chains) and TPV (chain B) 
complexes exhibit larger flap movements as compared to other two complexes.    
  
2.3.3 Cross-correlation analysis  
To understand the alterations of internal dynamics due to drug binding in C-SA PR, 
crosscorrelation matrices were calculated for apo, natural substrate and four drug bound protein 
complexes by the CPPTRAJ program (39) on the equilibrated MD trajectories.  The results are 
depicted in Figure 4.  The cross-correlation plots for DRV and LPV complexes are provided in 
the supplementary materials.  Strongly correlated and anti-correlated movements are shown by 
positive (red and yellow) and negative (blue) spots, respectively.  The diagonal parts show 
obvious correlated movements.  The other regions rarely show highly correlated movements.  
The apo form was initially analyzed thoroughly and the most important parts of the matrices 
are highlighted with four regions R1-R4.  R1 and R2 represent the correlations observed with 
residues 10-40 and residues 60-90 of chain A and chain B, respectively.  These regions cover 
major parts of the fulcrum, hinge and cantilever regions and demonstrate correlation that may 
exist between fulcrum and cantilever.  Higher correlation indicates a possibility of concerted 
motions leading to flap opening.  It is observed from Figure 4 that comparing the apo form of 
the enzyme, the positive correlations of these regions (R1 and R2) are reduced in all complexes 
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except for the LPV—complex as indicated in Figure S5.  The R3 region points to the correlated 
movements observed near the flap region of chain A.  Although diagonal parts show strong 
correlated movements for obvious reasons, reduction of flap movements as well as interactions 
of flap residues with the substrate/ligand should reduce the positive correlation of this region.  
This phenomenon is observed for most of the analysed complexes.  Among these, the natural 
substrate complex displayed a relative increased correlation when compared to the inhibitor— 
complexes with the TPV complex showing the most decreased correlation in the R3 region.  
Therefore, by analysing the R1-R3 parts it can be inferred that higher flap movements are likely 
for the LPV—complex, where flap movements are considerably reduced for TPV followed by 
ATV and DRV.    
The R4 region represents correlation of residues 30-60 of chain A and 10ʹ-80ʹ of chain B.  The 
apo form exhibited anti-correlated movements in region R4 whereas for PI complexes the 
anticorrelated movements are significantly decreased.  One explanation for these phenomena 
may be the fact that all these PIs are known to interact with amino acids of both chains.  
Therefore, inhibitor binding helped in decreasing the anti-correlated movements in this region.   
Interestingly, DRV—complex showed the most positive correlation in this region (62, 63).    




Figure 4. Cross-correlation matrices of the fluctuations of the coordinates for Cα atoms around 
their mean positions for each complex over the 60 ns MD simulations.  
  
2.3.4 Hydrogen bonding interaction  
The general output data generated by hydrogen bonding are; identities of donor and acceptor 
atoms; frames, which defines the time step of the MD trajectories, fraction (Frac) which defines 
the portion of the total time during which the hydrogen bond was detected, average bond 
distance (AvgDist) between the heavy atom acceptor and the hydrogen atom, and the average 
bond angle (AvgAng) between the donor and acceptor atoms.  
The natural substrate appears to exhibits relatively stronger interactions with Arg8 in 
comparison to other amino acids of the protease, made possible by the proton donation of Arg8 
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to the oxygen atom of Asp of natural substrate (Table 3).  Our observations are in agreement 
with those reported in an experimental work by Prabu-Jeyabalan et al(70) where they observed 
Arg8/8', in addition to Asp29, Asp30/30' and Gln58', forming direct side chain hydrogen bond 
interactions with the substrate peptides.  Table 3 also reveals that hydrogen bond interactions 
between the natural substrate and the enzyme was also observed in the flap tip and active site 
region, with the Gly48/48' and Asp30 residues being responsible for the interaction in these 
two regions, respectively.  Figure S6 properly indicates the interaction of Gly residues in the 
flap tip region of the protease with the natural substrate.  
Hydrogen-bond interactions were also monitored around the regions of the flap tips and the 
active site for the protease inhibitor—complexes. The most significant hydrogen bonds 
observed for ATV were with the active site residues, Asp29 and Asp29' (Asp29 of chain B).   
That is possibly one of the contributing factors to its relatively high binding affinity (Table 1).   
These results also show that the hydrogen bond interaction between ATV and the flap residue 
Gly48, also reported by Clemente et al. (71) may contribute to the relatively short distance 
between the flap tip (Ile50) and active site residues (Asp25) in chain A, in comparison to the 
other inhibitors where Gly48 is located.  It can be seen from the 3D structure in Figure S7 that  
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Table 3. Hydrogen bond interaction occurring between the ligand and residues in the active 
site and flap tip region of the protease for different bound systems.   
  
Complex  





  ARG_199—OD1a  ARG_8—NH2d  25284  0.4214  2.8250  156.8562  
NS  ARG_199—OD2b  ARG_8—NH2  25071  0.4178  2.8252  157.0978  
  ARG_199—OD2  ARG_8—NH1c  21877  0.3646  2.8444  161.1716  
  ARG_199—OD1  ARG_8—NH1  20601  0.3433  2.8446  161.6852  
  GLY_148—O  ARG_199—N  18791  0.3132  2.8875  152.5882  
  GLY_48—O  ARG_199—N  5391  0.0898  2.9047  157.3447  
  ARG_199—O  GLY_148—N  2791  0.0465  2.8940  149.2057  
  ASP_30—OD2  ARG_199—NZ  2641  0.0440  2.8040  150.9800  
  GLY_27—O  ARG_199—N  2187  0.0365  2.8982  152.0820  
  ASP_30—OD1  ARG_199—NZ  1920  0.0320  2.8074  151.9607  
  GLY_147—O  ARG_199—N  994  0.0166  2.9076  154.7709  
  ARG_199—O  ARG_107—NH2  833  0.0139  2.8824  146.6713  
  ARG_199—O  GLY_147—N  824  0.0137  2.8909  157.1457  
  ASP_29—OD2  ARG_199—NZ  712  0.0119  2.8125  152.7634  
  GLY_49—O  ARG_199—NH1  564  0.0094  2.8646  156.6636  
  DR7_199—OAJf  ASP_29—N  10814  0.1802  2.9057  158.4132  
ATV  DR7_199—OAIg  ASP_128—N  6052  0.1009  2.8997  160.4608  
  DR7_199—OAI  DR7_199—OAMh  4315  0.0719  2.8923  153.6036  
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  GLY_48—O  DR7_199—NBi  3579  0.0597  2.9161  155.2569  
  GLY_147—O  DR7_199—N  494  0.0082  2.9196  159.4964  
  AB1_199—O2  ILE_149—N  6073  0.1012  2.9022  150.4994  
  AB1_199—O3  GLY_48—N  3899  0.0650  2.9175  149.0338  
LPV  GLY_27—O  AB1_199—O4  846  0.0141  2.8719  150.3595  
  ASP_124—OD2  AB1_199—O4  388  0.0065  2.8582  156.3095  
 
  TPV_199—O31j  GLY_48—N  47862  0.7977  2.8471  161.3949  
  TPV_199—O31  GLY_49—N  20977  0.3496  2.8445  149.6769  
TPV  ASP_124—OD1  TPV_199—O8  15684  0.2614  2.8294  161.6918  
  TPV_199—O7  ILE_149—N  9397  0.1566  2.9152  157.4545  
  ASP_124—OD2  TPV_199—O8  3544  0.0591  2.8290  160.8629  
  ASH_25—OD1  TPV_199—O8  3473  0.0579  2.8792  148.4075  
  ASH_25—OD2  TPV_199—@O8  338  0.0056  2.9178  155.8354  
 
aOD1 and bOD2: First and Second oxygen treated as proton acceptors in ARG, respectively.  cNH1 and dNH2: First and Second 
hydrogen donated by the proton donor nitrogen, respectively. eNZ: One of the terminal nitrogen of the natural substrate to 
donate a proton. fOAJ, gOAI and hOAM: Oxygen atoms of ATV treated as hydrogen acceptors. iNB: Nitrogen atom of ATV 
treated as proton donor. jO31: One of oxygen atom of TPV treated as proton acceptor.  
  
NOTE: DRV displayed extremely low bond fraction (appr. zero) and as such it was not included in Table 3 but it is included 
in the supplementary material.(Table S1)  
  
It is interesting to note that TPV, in comparison to ATV, was observed to have a strong 
interaction with Ile50' (represented as Ile149) in the flap tip region.  This result in a shorter 
distance between TPV and the flap tip residue.  This clearly supports the observed results of a 
short distance between Asp25 and Ile50 of monomer B where Ile50' is located.  The RMSF 
also does supports this observation as it was shown from Figure 2 that Ile50 of chain B 
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displayed better stability.  The 3-D structures reported in Figure S9 also clearly show that TPV 
has more HB interactions with the flap tip residues than ATV.    
Figures S8 and S9 highlight an important factor that distinguishes the interaction of TPV from 
DRV despite both having sulfonamide moieties.  It is noted that the sulfonamide group in TPV 
has a partially exposure to the solvent while that of DRV is completely buried. The partial 
exposure of the sulfonamide group in TPV seems to display consistency with the low enthalpy 
of the TPV—complex (Table 1).  
2.3.5 Per-residue decomposition analysis  
The binding free energy was decomposed into contributions from the individual residues of the 
protein to gain insight into the role of particular residues in the binding mechanism of different 
ligands(72).  Post-dynamic binding free energy calculations using the MM/GBSA approach 
were performed for four drug-complex systems.  The results are illustrated in Figure 5 and 6.  
Figure 5 depicts the decomposition energy of ATV and DRV complexes and it can be seen that 
ATV demonstrated increased electrostatic interaction energy compared to DRV—PR complex 
(complying with the results of MM-GBSA binding free energy analyses).  DRV—PR exhibited 
high favourable electrostatic interactions (complying with the theoretical binding energy 
analyses results, Table 1) with amino acids like Asp29, Asp30, Gly48, Gly49, Ile50, Asp25ʹ,  
Ala26ʹ, Gly49ʹ and Ile49ʹ.  These interactions either are reduced or absent in the ATV—PR 
complex.  This is in good agreement with theoretical binding energy analyses results (Table 1).  
However, these strong favourable electrostatic interactions of DRV are compensated by strong 
unfavourable electrostatic interactions with Arg8ʹ, Asp 30ʹ, Ala8, Ala28, Ile47 and Asp29ʹ.    




Figure 5. Per-residue decomposition profiles of the ATV and DRV complexes using the 
MMGBSA approach.  
  
Van der Waals interactions with Ile50, Ile50ʹ and Ile84 have important contributions in overall 
binding energy of ATV—PR.  Furthermore, ATV depicted a tendency to develop hydrophobic 
interactions with most of the important binding site residues.  In DRV—PR, these van der 
Waals interactions are reduced causing an overall lowering of binding energy (Table 1).  A 
higher ∆Gsolvation was recorded for DRV complex in MM-GBSA analyses (Table 1).  High 
positive solvation energy was also observed for DRV—complex due to interactions with amino 
acids Asp29, Asp30, Asp25ʹ, Gly48ʹ, Gly49ʹ and Ile50ʹ (Figure 5).  Negative polar solvation 
energy as well as positive electrostatic energy for Arg8ʹ, Asp29ʹ and Asp30ʹ indicate that these 
amino acids may be involved in water mediated interactions with DRV.    
Figure 6 illustrates per residue decomposition energies of LPV—PR and TPV—PR.  Overall, 
the TPV complex results indicate larger electrostatic interactions compared the LPV— 
complex, especially around the active site and flap tip residues.  This interaction is thought to 
reduce the flexibility of the flap tip region as seen from the RMSF and flap-tip distance plots 
(Figures 2 and 3A) whereby TPV—complex displayed quite a reduced flexibility showed by 




Figure 6. Per-residue decomposition profiles for the LPV and TPV complexes using the 
MM/GBSA approach.  
  
The LPV complex exhibits favourable electrostatic interactions with amino acids such as  
Asp25, Gly27, Asp29, Asp30, Gly49, Asp25ʹ, Asp29ʹ and Gly48ʹ.  However, unfavourable  
electrostatic interactions are also observed with Arg8, Ala28 and Arg8ʹ.  Favourable van der  
Waals interactions with Ile47, Gly49, Ile50, Gly48ʹ, Gly49ʹ and Ile50ʹ were found.  The TPV 
complex demonstrated strong electrostatic interactions with residues such as Asp29, Asp30,  
Ile47, Gly48, Gly49, Asp25ʹ, Asp29ʹ, Gly49ʹ and Ile50ʹ.  Similar to DRV complex, TPV— 
PR revealed strong positive electrostatic potential as well as negative solvation free energy 
with Arg8ʹ.  However, the major factor that contributed to the lower theoretical binding 
energy (Table 1) is the positive polar solvation energy.  These solvation energies, which 
extended up to 6-7 kcal/mol, are mainly observed with Asp29 and Asp25ʹ.  Furthermore, 
van der Waals interactions were compromised to a considerable extent for TPV complex 
especially with the flap residues.    
Decomposition energy for the natural substrate complex in Figure S4 clearly shows that 
Asp29 and Asp30 of the protease exhibit extremely stronger electrostatic interactions with 
the substrate.  Some of the residues surrounding the active site (Asp29 & Thr30) show to 
display larger electrostatic interaction for the natural substrate compared to those observed 
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for inhibitors. This particular observation is thought to contribute towards the high binding 
affinity of the natural substrate compared to the inhibitors.  
2.3.6 Principal Component Analysis (PCA)  
To explore the nature of the motions in the HIV-1 PR enzyme, PCA was carried out.  This 
analysis highlights in a qualitative manner the effect of the inhibitor’s binding on the 
conformational motion in the HIV-1 PR.  Based on the porcupine plots (Figure 7), it is evident 
that inhibitor binding reduced the overall movement of the enzyme as compared to the apo 
form.  Furthermore, the apo form showed higher fluctuations in the cantilever (residues 66-70) 
and fulcrum regions.  All complexes showed anti-symmetric movement patterns in fulcrum, 
hinge and cantilever regions.    
  
Figure 7. Collective motions corresponding to PC1 obtained by performing principal 
component analysis on a 60 ns MD simulation trajectory after the equilibrium (the protein part 
is presented in red ribbon, higher fluctuating parts are presented in grey and blue).  
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The Figure 7 does indicate that the binding of the natural substrate makes the protease more 
rigid and it is evident that the complex had mixed patterns of motions in most regions of the 
enzyme.  The ATV—PR showed increased fluctuations in three regions of chain A.  The hinge 
region (residues 35-42), part of fulcrum (residues 15-19) and residues 82-84.  Such large 
fluctuations were not observed in the other chain (chain B) indicating an anti-symmetric 
movement of the complex.  Such anti-symmetric movement was also found in the distance 
analyses (Figure 3B and 3C, the Asp25-Ile50 distance was shifted to a considerable extent for 
chain A and chain B).  In chain B, the ATV—PR exhibits horizontal movements between 
fulcrum, hinge and cantilever regions that may facilitate horizontal hydrophobic sliding (73).    
Similarly, for DRV the cantilever region of Chain A (residues 66-70) was also found to have 
larger vertical fluctuations (Figure S10).  DRV—PR also demonstrated higher vertical 
fluctuations in fulcrum regions of both chains (residues 14-18).  Similar types of movements 
were also observed with LPV—PR that depicted significant asymmetric fluctuations at the 
cantilever region of chain A (residues 66-70) (Figure S10).  Both chains of the cantilever region 
of TPV—PR depicted larger vertical movements than other parts of the enzyme complex.  Only  
ATV-PR showed partial horizontal movement between the fulcrum and cantilever regions (in 
Chain A) which is indicative of the proper hydrophobic sliding.  When combining the PCA 
results with the correlation matrix analyses (Figure 4) it may be assumed that LVP—PR and  
TVP—PR may have vertical movements in fulcrum and cantilever regions in both monomers.  
Such movements are indicative of distorted hydrophobic sliding (73).  Such perturbed sliding 
between fulcrum and cantilever regions reduces hydrophobic interactions (hydrophobic core) 
in the enzyme system and affects receptor ligand interactions as well (73).    
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2.4 Conclusion  
Several factors affect the binding of protease inhibitors through altering the flexibility of HIV1 
protease flaps, the most crucial part of the enzyme in ensuring the catalytic function of the 
enzyme.  It is also interesting to note that this study has been able to bring together two major 
components in protease complexing with inhibitors; binding of protease inhibitors onto the 
active site and the interaction of the inhibitors with the flaps of the protease causing it to be 
inactive.  Higher hydrophobic interactions were found to be major contributing factor for higher 
binding affinity of ATV and this could be attributed to the higher active site volume and higher 
of flap stability.  The hydrophobic interactions are highly compromised for the DRV and TPV 
complexes.  
All complexes showed more stability in the flap dynamics compared to the apo form.  However, 
none of the complexes achieved fully closed form in the entire simulation.  Although flap— tip 
distances of the complexes were found to overlap with each other, LPV and DRV complexes 
showed comparatively larger flap tip distances versus ATV—PR and DRV—PR.  Furthermore, 
the active site of DRV—PR was predicted to be larger than LPV—PR and TPV—PR.   
The distance and angle analyses also highlighted that TPV and LPV and have greater flap 
curling and movement compared to the other two complexes.  One important characteristic of 
DRV is that it does not interact with residues outside the binding pocket(74).  Therefore, the 
size of the active site volume may not directly affect its overall interactions.  Interestingly, ATV 
and LPV showed almost similar patterns of interactions as the values of enthalpy and entropic 
contributions were found to follow a comparable trend.  Both these complexes showed higher 
entropy than DRV—PR and TPV—PR.  The TVP—PR showed lowered theoretical binding 
energy is owed to its high solvation free energy as well as lower van der Waals interactions.  It 
was also observed that binding of inhibitors may slightly alter the hydrophobic core of the 
complexes leading towards variations in overall flap dynamics as well as stabilities of the 
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inhibitors at the active sites.  The correlation matrix analyses, principal component, as well as 
hydrogen bond analyses, indicated that the possibilities of hydrophobic sliding are slightly 
higher in ATV complex.  The lower binding affinity of TPV may be attributed to high solvation 
free energy as well as lower hydrophobic interactions.  In conclusion, our findings reveal the 
complexity of drug—PR interactions and that emphasis on protease inhibition shouldn’t only 
be made on the binding affinities of protease inhibitors into the active site but also interactions 
with the flap region has shown to be critical in ensuring that the flexibility of the flaps is 
reduced. These should be considered for drug development of protease inhibitors which possess 
the two characteristics; higher binding affinity and good interactions with the flap region.   
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Abstract   
The HIV-1 PR possesses three key dimer interface regions; flap tips, active site and the β-sheet 
interface. Residues located at these regions are known to have a vital role in maintaining the 
stability of the protease as these residues are highly conserved for most drug-resistant strains.  
In this study, we attempt to disrupt the dimeric nature of the protease by truncating the C- and 
N- terminal residues on the South African subtype and thus inducing inactivation of the 
enzyme.  Successful destabilization of HIV binding in this way will provide structural details 
at the molecular level about the β-sheet interface as potential target for HIV inhibition.  
MMGBSA calculations were performed and showed that truncation led to a substantial drop in 
binding affinities whereby the natural substrate reduced its binding free energy from -36.15 to 
-28.13 and -23.48 kcal/mol for single and double truncated systems, respectively.  The loss of 
many key hydrogen bond interactions was seen as a very important factor which contributed to 
the collapse of the dimeric structure of HIV-1 PR.  This study not only compliments several 
experimental findings recorded on the dimerization inhibition but also provides a detailed 
analysis on what key factors contribute significantly to the destabilization of the HIV-1 C-SA 
PR through disruption of the β-sheet interface.    






3.1 Introduction  
  
Dimerization of HIV-1 PR monomers to form a homodimer has been found to be a key factor 
in ensuring that the protease enzyme achieve its catalytic activity1, 2.  The HIV-1 PR monomers 
are held together by several polar and nonpolar interactions which contributes to its stability1.   
The dimer interface constitutes of the N- and C-terminal anti-parallel β-strands (residues 1-5 
and 94-99, the β-sheet interface), active site (residues 24-29), helices (residues 84-93) and the 
flap tips (residues 48-54), which are found to be highly conserved regions of the protease3-5.   
  
Figure 1. Illustration of three important regions of dimerization interface of HIV-1 PR.  
  
Despite the fact that the monomeric state of HIV-1 PR is believed to possess structural stability, 
it is however inactive6-8 indicating the significance of dimerization of HIV-1 PR subunits for 
proteolytic activity of the enzyme.  Several studies have reported disruption of the dimeric state 
as a possible target for protease inhibition4, 9-12.  These studies have highlighted alternative 
strategies for inhibitory mechanisms to active site–directed inhibition.  There have been several 
studies reported on drug resistance of several active site inhibitors as a result of mutations 
occurring in the binding pocket of the protease13.  These studies have shown that destabilization 
of a dimer interface can be a viable inhibition mechanism for HIV-1 PR.  
Earlier reported studies on C- and N-terminally cross-linked peptides were designed to mimic 
the intertwined dimer interface of HIV PR9, 10.  Despite their success in dimerization inhibitory 
activity, these agents displayed quite high molecular complexities14.  Developments were later 
achieved when inhibitors of low molecular weight were eventually proposed, and these were 
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based on short ‘interface’ peptide segments.  Some of these agents showed high inhibitory 
power against HIV PR as shown by their low nanomolar Ki values
14, 15.    
Bannwarth et al.4 developed improved lipopeptides that had several chains of different amino 
acid sequence with different lengths.  The authors demonstrated that all of the cross-linked 
peptides with flexible spacers displayed less efficiency compared to the alkyl peptides4, 10.  
Another exploration of the dimer interface was performed by Naicker et al.5 and also 
highlighted the disruption of the dimer interface for inactivation of the enzyme.  The residue 
Phe99 situated at the terminal end of the chain was mutated to Ala to determine the contribution 
brought upon by the residue to the South African HIV-1 subtype C protease.  The study 
demonstrated that no activity was attained by the Phe99Ala mutated protease and as such, the 
report suggested that the mutant displayed a monomeric nature because of a reduced β-sheet 
content.   
It has been reported that one possible way of disrupting the dimer interface of HIV-1 PR is by 
truncation of the terminal residues from the β-sheet interface region16.  The authors used a 
molecular dynamics approach to simulate different states of the subtype B wild-type complex 
and showed that by truncating four residues from each terminal ends of the HIV-1 PR subunits, 
a less compact structure is achieved, which they proposed should ultimately lead to HIV-1 PR 
deactivation.  
Given these findings, our study utilized a molecular dynamics approach to analyse the 
effectiveness of removing the five terminal residues from both ends of one and both subunits 
of HIV-1 PR.  The primary objective for the MD simulation was to determine the effect that 
truncation has on the binding affinity of the South African HIV-1 subtype C PR.  Secondly, the 
interest of this study was also to further explore how other dimer interface regions get affected 
by the disruption at the β-sheet dimer interface.  In addition to the apo and natural substrate 
bound systems, inhibitor-bound systems of atazanavir (ATV) and tipranavir (TPV) were also 
considered so as to explore how their inhibitory strengths are affected by truncation.    
3.2 Computational Methods  
  
3.2.1 Preparation of inhibitors/enzyme complex  
  
The following PDB codes were used to obtain complex crystal structures from the Protein Data  
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Bank; 3U71 (apo/free), 3EL1 (ATV), 2O4P (TPV) and 1KJH (natural substrate).  The same 
computational methods as employed for our recent paper17 were also followed.  Five residues 
from N- and C- terminals were selectively removed from subunit A to obtain single truncation 
and five residues were also removed from N and C terminals from both subunits to obtain a 
double-truncated system.  
3.2.2 Setting up the system for Molecular Dynamics (MD) simulations  
  
Prior to molecular dynamics simulations, the protonation states of residues of HIV-1 C-SA 
were assigned at pH=7.0 using the PropKa server18, 19.  The ff99SB20 and the general AMBER 
force field (GAFF)21 were used to describe the inhibitor–protein and inhibitor–solvent 
interactions, respectively.  The ligands were parameterized with Leap21 implemented in Amber 
14, using the general AMBERforce field (GAFF)21 in Antechamber. MD simulations were 
performed using Amber 14 with the ff99SB22 force field with the TIP3P23 explicit water in 
acubic box with 8 Å distance around the complex.  The positive charge of the complexes were 
neutralized with chloride ions. Partial Mesh Ewald (PME) 20 method was used to consider long 
range electrostatic forces (cutoff 12 Å).  Additionally, the SHAKE algorithm24 was used to 
constrain all bonds to hydrogen atoms.  To reduce the overlapping atom interactions of initially 
prepared solvated complexes, energy minimization was performed in two stages.  In the first 
stage only ions and water molecules were relaxed by 2000 step minimization process (1000 
steps of steepest decent minimization followed by 1000 of conjugated gradient) using a 
restrained force of 500 kcal/mol on the solute.  For the second stage of minimization, the whole 
system was relaxed by a 5000 step minimization process (2500 steps of desent minimization 
followed by 2500 of conjugated gradient).  The minimized systems were gradually heated up 
from 0 to 300 K with a weak harmonic restraint of 10 kcal/mol to keep the solute fixed for 200 
ps.  Subsequently, the 2 ns constant pressure equilibrations at 300 K were performed.  Lastly, 
100 ns MD simulations without restriction were run at a constant temperature of 300 K and 
constant pressure of 1 atm.  
3.2.3 Post-dynamics analysis  
  
After all 100 ns MD simulations had finished, analyses for the root-mean square deviation 
(RMSD), root-mean square fluctuation (RMSF) and other various distance analyses were 





3.2.4 Binding free energy calculations  
  
Molecular Mechanics/Generalized Born Surface Area (MM-GBSA)26 binding free energies of 
inhibitors were calculated using MM-PBSA program in Amber 14.  For each complex, 400 
snapshots were taken from the last 2000 ps of the 100 ns MD trajectory with an interval of 5 
ps.  The binding energy is represented as:   
∆𝐺 = ∆𝐸𝑒𝑙𝑒 + ∆𝐸𝑣𝑑𝑊 + ∆𝐺𝑝𝑜𝑙 + ∆𝐺𝑛𝑜𝑝𝑜𝑙 − 𝑇∆𝑆  
The first two terms ∆Eele and ∆EvdW are calculated by molecular mechanisms and represents 
the electrostatic and van der Waals interactions with the proteins in gas phase.  The polar 
solvation free energy ∆Gpol is calculated by using the MM-PBSA program27 and it represents 
polar interactions with the solvent molecules.  The ∆Gnonpol signifies non-polar solvation free 
energy and is obtained from the equation ∆𝐺𝑛𝑜𝑛𝑝𝑜𝑙𝑎𝑟 = 𝛾𝑆𝐴𝑆𝐴 + 𝛽 28 .  The solvent accessible 
surface area (SASA), the surface tension proportionality constant (γ) and the free energy of 
nonpolar solvation of a point solute (𝛽), were set to 0.00542 kcal mol-1 Å-2 and 0 kcal mol-1, 
respectively29.  The entropy contribution to the binding free energies were calculated using 
normal mode analysis29-32 for the complexes from changes in the translational, rotational and 
vibrational entropy components (Table 1).  
3.2.5 Per residue free energy decomposition analysis  
  
To evaluate the contributions of individual residues to the total binding free energies of the 
inhibitors/PR complexes were computed using the MM-GBSA per residue free energy 
decomposition method29, 33 in Amber 1426.  All energy components including van der Waals, 
electrostatic, polar solvation and nonpolar solvation contributions were all calculated using 400 
snapshots extracted from the last 2000 ps MD trajectories (Figure 5 and 6) of the 100 ns MD 






3.3 Results and discussion  
  
3.3.1 Stability and flexibility of the HIV-1 PR complexes  
  
In order to gain insight into the structural drift of the simulated systems from the initial 
coordinates, the root mean square deviation (RMSD) of the Cα backbone was monitored 
throughout the 100 ns MD simulations.  
  
Figure 2. Root Mean Square Deviation of the backbone Cα atoms for the native (untruncated), 
single and double-truncated systems of (A) Apo enzyme, (B) Natural substrate (NS), (C) ATV 
complex and (D) TPV complex over the 100 ns MD trajectory.    
  
The RMSD plot of the apo enzyme shows that the truncated systems displayed slightly higher 
RMSD values compared to the native form which displayed approximately 1.5 Å of RMSD on 
average.  The RMSD displayed by the truncated systems of the natural substrate complex 
(Figure 2 B) and inhibitor-bound complexes (Figure 2 C and D) were higher than their native 
counterparts were.  Three different MD simulations of Apo enzyme were carried out by varying 
initial atomic coordinates or initial atomic velocities. RMSD plots of these conformations 
showed that they displayed relatively similar stability (Figure S1, Supplementary Material).  
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3.3.2 Root-Mean Square Fluctuation (RMSF)  
  
To understand the fluctuation of each residue over the 100 ns MD simulation, the root-mean 
square fluctuation (RMSF) was analysed.  The analysis provided insight into the flexible 
regions of the protein for the native and truncated forms.   
  
Figure 3. Root-Mean Square Fluctuation of backbone atoms against residue number for the 
APO and NS systems in native form over the 100 ns MD trajectory.  
  
  
Figure 4. Root-Mean Square Fluctuation of backbone atoms against residue number for the 




Figure 5. Root-Mean Square Fluctuation of backbone atoms against residue number for the 
APO and NS systems in double-truncated (DT) form over the 100 ns MD trajectory.  
  
Plot of native forms for systems of APO and NS demonstrate that both systems displayed higher 
fluctuations for most residues particularly around the flap region.  Figures 4 and 5 demonstrate 
that the active site residues gained significant fluctuations as a result of truncation at the N- and 
C-terminal residues.  The RMSF values attained by the active site residues of the ST and DT 
forms of NS complex reached 1.69 and 2.49 Å, respectively, while that for the native enzyme 
(untruncated) reached approximately 0.6 Å.  This indicates that the truncated forms experience 
much more movement at the active site.   
The TPV-ST result shows that when only chain A is truncated, most residues in chain A 
displayed relatively higher fluctuations as indicated in Figure S3 compared to Figure S2 of 
Supplementary Material. The increased fluctuation observed for the truncated systems 
corresponds well with the decrease in binding free energies recorded in Table 1.  Fluctuations 
of the Cα atom for each residue of the double-truncated systems are depicted in Figure S4 
(Supplementary Material). According to the RMSF plot in figure S4, it is evident that the flap 
tip residues displayed a decrease in fluctuations and this supports the idea that the flap tip 
residues became more rigid as a result of double truncation. The loss in flexibility (increase in 
rigidity) at the flap tips ensured that the residues in this region supplement for the loss of 




3.3.3 MM-GBSA binding energy analyses   
  
To understand the effects of truncation of the N and C-terminal residues on binding inhibitors 
to the C-SA truncated PR, the binding free energies and their components ( ∆Evdw, ∆Eelec, ∆Ggas,  
∆Gpolar,  ∆Gnonpolar TΔS and ∆Gbind ) were calculated for all systems using the  MM-GBSA 
approach and normal mode analysis (NMA).  
As shown in Table 1, the calculated binding free energies of the truncated systems demonstrate 
a decrease compared to their respective native systems.  The double-truncated system of the 
natural substrate (NS) seemed to display a greater decrease in binding free energy (∆Gbind), 
with an energy difference of 12.67 kcal/mol while that of ST differed by approximately 8.02 
kcal/mol.  It is thought that the negative value (-68.27 kcal/mol) observed for polar solvation 
free energy (∆Gpolar) of the double-truncated NS Native case was due to the highly unfavourable 
intermolecular electrostatic interactions of this substrate complex.  
  
Table 1. Calculated binding free energies [∆Gbind] and its components for two HIV-1 protease 
inhibitors and the natural substrate (NS) on C-SA PR. All data values are in kcal/mol.  
Complex
a
 ∆Evdw ∆Eelec  ∆Gpolar ∆Gnonpolar  -TΔS ∆H ∆Gbind 
NS Native -86.49 4.69  24.15 -11.76  33.26 -69.41 -36.15 
ST -83.65 12.01  23.35 -11.50  31.66 -59.79 -28.13 
DT -75.70 97.26  -68.27 -10.122  33.39 -56.84 -23.48 
ATV Native -76.27 -6.948  29.25 -9.66  29.26 -63.63 -34.37 
ST -57.54 -4.067  21.90 -6.99  25.21 -46.70 -21.49 
DT -71.78 -10.36  33.41 -9.11  29.65 -57.84 -28.20 
TPV Native -59.96 -37.93  58.49 -8.30  27.79 -47.70 -19.91 
ST -45.93 -6.54  25.14 -6.50  24.06 -33.83 -9.77 
DT -55.14 -25.53  46.50 -7.31  26.32 -41.49 -15.17 
 
Since the electrostatic interactions were unfavourable (97.26 kcal/mol) it makes sense that an 
overcompensation by the desolvation of polar groups34-36 was necessary.  
The truncated systems of the inhibitor complexes (ATV and TPV) also demonstrated a decrease 
in the calculated binding energy compared to their native counterparts.  The single truncated 
system of the ATV complex displayed a binding free energy of -21.49 kcal/mol, which is an 
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energy difference of approximately 12.88 kcal/mol and the energy difference attained by the 
double-truncated system was 6.17 kcal/mol.  
A decline of the binding free energy for the truncated systems was also displayed for TPV as 
Table 1 clearly demonstrates an energy difference of 10.14 and 4.74 kcal/mol for ST and DT, 
respectively.  The observed decrease in binding free energy for the truncated systems of the 
natural substrate, ATV and TPV complexes is related to the disruption of the β-sheet dimer 
interface. These results also correlate with the distance analysis carried out (Figure 10) for two 
residues (Gln92 and Gln92') situated close to the terminal residues at the β-sheet and this 
distance was found to increase when truncation of terminal residues was done.  A decrease in 
binding free energy for these systems shows that the reduction of interactions known to occur 
at the β-sheet dimer interface has an important impact in destabilizing the protease dimer.  
3.3.4 Per-residue free energy decomposition analysis  
  
In order to gain a further insight into the binding energies for the studied systems and the role 
of particular residues involved in the binding mechanism, binding free energy was decomposed 
into contributions from various residue pairs of certain regions.  Figures 6, 7 and 8 show 
contributions from residues in the active site as well as the flap tip region, these being the two 
other dimer interface regions.  
According to Figure 6, the two catalytic aspartates for chain A and B display different energy 
contributions as the aspartate of chain B aspartate offers far greater electrostatic contributions 
compared to that of chain A.  There seems to be a symmetrical contribution from these two 
aspartates of HIV-1 PR when the natural substrate-complex is truncated and also the 
electrostatic contribution is greater compared to the untruncated (native) system.  The 
substantial rise in electrostatic contribution by the catalytic aspartates is confirmed by the high 
values displayed in the RMSF plot (Figure 5) with fluctuation reaching values of approximately  




Figure 6. Plot of per-residue decomposition analysis for the native natural substrate complex 
(NS-Native).  
  
It is clear that only Ile50 for chain A had a significant contribution to the binding of the natural 
substrate to the HIV-1 PR in the native form.  This effect was also displayed by Ile50 of chain 
B (Ile149) with a total energy contribution of approximately -9.5 kcal/mol as indicated in 
Figure 7 and 8.  The two Ile50 residues also made notable contribution to the van der Waals 
interactions in the native form.  Finally, the destabilization effect of both Asp 25 and Asp 124 





Figure 7. Plot of per-residue decomposition for the single-truncated system of the natural 
substrate complex (NS-ST).  
  








3.3.5 Radius of Gyration (Rg)    
  
Radius of Gyration (Rg) over the 100 ns MD simulation was used to better explain the 
compactness of the native and truncated systems as a result of the overall folding or unfolding.   
The distribution of the radius of gyration values is represented in Figure 9 A and B.   
  
Figure 9. The plot of radius of gyration for three different systems; native, ST and DT of (A) 
apo enzyme, (B) natural substrate complex.  
  
It is quite evident from Figure 9 that the truncated systems of all prepared complexes 
demonstrated significantly higher Rg values when compared to the native systems.  The 
average Rg values for the APO systems increase from 17.08 Å for the native form to 17.48 and 
17.95 for ST and DT forms, respectively.  A similar trend was also observed for the NS complex 
systems whereby average Rg values of 16.98; 17.39; and 18.45 for native, ST and DT systems, 
respectively.  The increase in values attained by the truncated systems indicates less stability 
and as a result, less compactness.  These results correspond with the binding energies reported 
in Table 1 whereby the truncated systems displayed reduced binding energies compared to the 
native system.  The reduced compactness of truncated systems may be attributed to the collapse 
of the dimer interface which influenced the destabilization in the whole structure of the 
complexes by breaking of essential hydrogen bonds in the dimer interface.  The truncated 
systems of inhibitor-bound complexes also displayed less compactness as highlighted by an 






3.3.6 Distance Gln92-Gln92'  
  
The distance analysis was carried out to determine the extent to which residues near the β-sheet 
drift apart as result of truncation.  Glutamine at position 92 and 92' were chosen as these were 
conserved even for the truncated systems.   
Figure 10 A shows that the two residues started to drift apart for the native form of APO system 
after 20 ns when a single truncation was performed.  The distance was observed to increase 
with even greater fluctuation when truncation was performed in both chains of the protease. 
Figure 10 B does demonstrate an increase in the distance after 50 ns for the single truncated 
system of the natural substrate-bound complex.  An even greater separation of the residues was 
observed when double truncation of the C- and N-terminal residues was done whereby the 
residues separated by a distance of above 36 Å.   
  
Figure 10.  The plot of distance between Gln92 and Gln92' for situated near the β-sheet for the 
different systems, Native, ST and DT of (A) Apo enzyme, (B) natural substrate complex.  
  
The inhibitor-bound systems also showed a similar display of the increase in distance between 
the two residues (Figure S7, Supplementary Material).  This analysis confirms the trend 
displayed in the MM-GBSA binding energies recorded in Table 1 where the double-truncated 






3.3.7 Distance Ile50-Ile50'  
  
A distance between the Cα atoms of the flap tip residues (I50 & I50') from both subunits was 
examined in order to determine the extent of flap opening.  The distances obtained for all 
systems did not display any particular trend as there were some considerable overlaps 
demonstrated.  The flap tip distances displayed by all systems of the natural substrate complex 
overlapped throughout the 100 ns MD simulation.  It is demonstrated in Figure 11 B that the 
double truncated system showed the lowest distance between the flap tips for most part of the 
simulation.    
  
Figure 11.  The distance (Å) between the flap tip residues (Ile50 and Ile50') for three different 
systems; native, ST and DT of the (A) apo form and (B) natural substrate complex obtained 
from a 100 MD simulation.  
  
As was pointed out by previous studies,37, 38 this metric may sometimes not be an adequate 
parameter for analysis of flap opening as flap tip distance is affected by the curling in of the 
flap tips and also the asymmetry of the flaps.  However, the flap tip distance measured for the 
inhibitor bound complexes for ATV and TPV show that the double truncated systems attained 
reduced values when compared to those of native systems as indicated in Figure S6 
(Supplementary Material).  Plots of flap tip distance are represented in This is as a result of 
the flap tips of the PR coming even closer to compensate for the loss of dimerization on one of 
it dimer interface regions as the inhibitors used in this study are those that are designed to bind 
onto the active site region and induce a closed conformation.  Other supporting evidence for 
this result is the per residue decomposition analysis of the truncated systems of ATV (Figure 
S8-S10, Supplementary Material) where despite the loss of significant binding contributions 
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by the catalytic aspartate residues, the flap tip residues still exhibited significant per residue 
contributions towards the overall binding process.   
  
3.3.8 Hydrogen Bond (Arg8-Asp29'/ Asp29-Arg8')  
 
Residues Arg8 of subunit A and Asp29 of subunit B have been shown to form a salt-bridge 
interaction and positioned at the outer edge of the cavity16 and as such, the distance between 
them was monitored throughout the simulation to determine the effect of truncation on the 
interaction of these residues.  Figure 12 shows where the two residues are located and gives a 
clear indication of how the separation of these residues can represent the separation of the two 
subunits. To better analyse the effect of this salt-bridge, we also performed HB analysis on the 
other edge of the cavity using Asp29-Arg8' as interacting residues.  The strength of the 
hydrogen bond interaction at this salt bridge is recorded in Table 2 and 3.  
  
  
Figure 12.  A 3-D illustration of the two residues (Arg8 and Asp29') that form a salt-bridge in 
HIV-1 PR.  





Table 2. Hydrogen Bond interaction formed between Asp29/29' and Arg8/8' of APO enzyme 
for the native and truncated systems.  
  
#Acceptor Donor Frames Frac AvgDist AvgAng 
APO Native      
ASP_29@OD2 ARG_107@NH2 44408 0.4441 2.7822 160.9139 
ASP_29@OD1 ARG_107@NH2 43006 0.4301 2.7811 160.9609 
ASP_29@OD1 ARG_107@NE 30597 0.306 2.8664 160.1509 
ASP_29@OD2 ARG_107@NE 29955 0.2995 2.8674 160.0251 
ASP_128@OD1 ARG_8@NH2 5393 0.0539 2.8028 160.4957 
ASP_128@OD2 ARG_8@NE 4831 0.0483 2.8495 160.111 
ASP_128@OD2 ARG_8@NH2 3337 0.0334 2.8207 159.1025 
ASP_128@OD1 ARG_8@NE 2977 0.0298 2.8514 159.4549 
ASP_128@OD2 ARG_8@NH1 741 0.0074 2.8011 152.4173 
ASP_128@OD1 ARG_8@NH1 669 0.0067 2.8181 153.0649 
ASP_128@OD1 ARG_8@NH2 644 0.0064 2.82 158.0249 
ASP_29@OD1 ARG_107@NH1 620 0.0062 2.8123 158.2965 
APO ST      
ASP_24@OD2 ARG_97@NH2 807 0.0079 2.798 160.1247 
ASP_24@OD1 ARG_97@NE 688 0.0067 2.8376 158.7441 
APO DT      
ARG_92@O ARG_92@NH1 919 0.009 2.8445 160.8413 
                  Frac (/100), AvgDist (Å), AvgAng (°)  
  
Table 2 shows that the native form of APO native system displayed a relatively high number 
of hydrogen bonds between Arg8/8' and Asp29/Asp29'.  However, both truncated systems 
showed fewer hydrogen bonding interactions.  The percentage of these bonds forming during 
the simulation is represented by the fraction (Frac) which indicates the proportion of the total 
time during which the hydrogen bond was detected.  The truncated systems displayed lower 
fractions when compared to the native forms for APO and NS.  The double truncated system 
of NS complex completely lost this salt bridge interaction as shown in Table 3 and also 











Table 3. Hydrogen Bond interaction formed between Asp29/29' and Arg8/8' of NS-complex 
for the native and truncated systems.  
#Acceptor  Donor  Frames  Frac  AvgDist  AvgAng  
NS Native            
ASP_29@OD1  ARG_107@NH2  46673  0.4667  2.77  162.0756  
ASP_128@OD1  ARG_8@NH2  46435  0.4643  2.7593  160.1163  
ASP_128@OD2  ARG_8@NH2  44957  0.4496  2.7581  161.162  
ASP_29@OD2  ARG_107@NH2  43667  0.4367  2.7737  161.6128  
ASP_128@OD2  ARG_8@NE  37259  0.3726  2.856  159.3066  
ASP_29@OD2  ARG_107@NE  33066  0.3307  2.8606  158.9933  
ASP_128@OD1  ARG_8@NE  32525  0.3252  2.8576  160.6622  
ASP_29@OD1  ARG_107@NE  32449  0.3245  2.8607  158.8056  
ASP_128@OD1  ASP_128@N  558  0.0056  2.8868  139.3175  
NS ST            
ASP_24@OD2  ARG_97@NH2  54297  0.543  2.7776  160.2575  
ASP_24@OD1  ARG_97@NE  33885  0.3388  2.8606  161.787  
ASP_24@OD1  ARG_97@NH2  32513  0.3251  2.8082  160.8726  
ASP_24@OD1  ARG_97@NH1  4468  0.0447  2.8425  150.5733  
ASP_24@OD2  ARG_97@NE  1933  0.0193  2.8924  145.3985  
ASP_24@OD1  ARG_97@NH2  1406  0.0141  2.8272  155.0197  
              Frac (/100), AvgDist (Å), AvgAng (°)  
  
To gain a better insight into the interaction of Asp29 and Arg8' we measured the distance 
between the Cα atoms of these residues to determine if there is any drifting occurring as a result 
of truncation.  Figure 13 shows that the distance between Arg8 and Asp29' for the apo enzyme 
seemed to slightly increase due to truncation.  The observed distance for the native form was 
between 6 and slightly over 8 Å while upon truncation the distance was observed to increase 
to values of 12 Å and above.  The double-truncated system of the NS complex displayed very 
high distances as compared to its native state and this clearly shows that truncation led to the 





Figure 13. Distance of Arg8 and Asp29' measured during the 100 ns MD simulation for the 
native and truncated forms of all systems studied.  
  
It is quite evident that upon truncation, the distance between the two residues tends to increase 
as a result of reduced flexibility of the HIV-1 PR.  The increase in the Arg8-Asp29' distance 
give an indication that the dimeric state of the protease collapses and also this could very well 
be associated with the decrease in binding energy values for the truncated systems as observed 
in Table 1.  
  
3.4 Conclusion    
  
Although many studies have looked into the β-sheet interface region as being a possible target 
for HIV-1 PR inhibition, we believe that not sufficient evaluation of what impact the disruption 
of this region has on other dimer interface regions has been recorded.  The detailed analyses 
performed in this study demonstrate that truncation of C- and N-terminal residues brings about 
destabilization to the dimeric structure of HIV-1 C-SA PR, which is the first study done for this 
particular subtype.  Destabilization of the dimeric form of HIV-1 PR led to many key hydrogen 
bond interactions to break which then led to poor binding pattern for the substrate as well as 
inhibitors.  The results clearly indicate that less compactness is achieved as a result of truncation 
of β-sheet residues.   
This study revealed that disruption of the β-sheet interface due to truncation induces fluctuation 
at the active site region, but the flap tips still managed to keep their distance close particularly 
when truncation was performed on both chains.  We have also been able to demonstrate that 
the inhibitors bound to a double-truncated protease displayed a larger increase in binding free 
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energy (approximately 6 kcal/mol) relative to single truncation.  This means that the 
inhibitorbound complexes prefer a symmetrical conformation within the protease.  Truncation 
leads to a drop in Gibbs free binding energy as result of loss of key molecular interactions in 
the active site region as was shown in the per-residue decomposition analysis.  The other 
contributing factor also discovered is the high fluctuation of the catalytic residues after 
truncation of the C- and N-terminal residues which led to the substrate and inhibitors not being 
able keep ideal binding interactions within the active site region.  This study therefore provides 
insight at the molecular level on what happens when dimerization of HIV is disrupted at the β-
sheet interface.   
In terms of compensating for the loss of one key dimer interface region, our results showed that 
despite the increase in fluctuation of catalytic aspartates, they seem to have a high electrostatic 
contribution towards binding free energy as a result of truncation.  Future studies should 
involve MD of a suitable dimerization inhibitor positioned at the β-sheet region to determine 
the nature of the interactions involved.  
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CHAPTER FOUR  
Summary and conclusion  
  
There are a reasonable number of studies that have calculated the binding free energies of 
commercial drugs in complex with HIV PR.  The nature of the interactions between the 
inhibitors of these drugs and the HIV PR is not well studied.  The fundamental aim of this work 
was to explore how flap dynamics is affected by various molecular interactions induced by the 
differing in binding affinities of inhibitors.  The study also looked into the factors that seem to 
influence the affinity of protease inhibitors towards the protease.  In addition, disruption of the 
dimeric nature of the protease was performed to induce less stability on the overall 
conformation and thus leading to inactivation of the enzyme.   
In chapter two (publication 1), a molecular dynamics study was successfully carried out to 
explore the flap dynamics of the South African subtype C HIV-1 PR over 60 ns simulation 
period in explicit solvent.  The MM-GBSA method showed a distinguishing factor in terms of 
binding affinities of stronger and weaker inhibitors by highlighting the largest van der Waals 
energy value observed for the ATV-enzyme complex as compared to that of the weaker value 
for the TPV-complex.  The stronger affinity of ATV towards the PR was also displayed by the 
per-residue decomposition whereby the active site residues of the C-SA PR displayed fairly 
significant contributions to the overall binding of ATV.  The per-residue decomposition 
analysis showed that the high contribution by the flap tip residues of the TPV-complex enables 
the flap tip region to be rigid and the complexed system to be reasonable stable, despite TPV 
lacking strong hydrogen bonding and key interactions at the active site region.  
The RMSD analysis demonstrated well equilibrated systems whereby the inhibitor-complexes 
maintained better dynamic stability.  The inhibitor-complexes attained less residual fluctuations 
compared to the unbound system.  The PCA analysis demonstrated that there seems to be a 
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reduction in overall movement of the HIV-1 PR as a result of complexation of the inhibitor to 
the enzyme.  Distance analysis highlighted the flap-tip distance attained by the  
ATV-complex as being very fixed compared to the complexed system of the weaker binder 
(TPV).  In addition, the active site-flap tip distance analysis revealed an unsymmetrical nature 
of the inhibitor-protease complex as was displayed by the differing trend in distances obtained 
for chain A and B of the PR.  
The angles measured between the flap tip residues demonstrate that the angle values were 
lowered when there a substrate or an inhibitor bound to the protease and this analysis also 
showed the flap tip residues being held at relative fixed positions.  The bound complexes 
displayed less twisting compared to the apo system as highlighted by the dihedral angle 
analysis.  Interestingly, the hydrogen bond analysis revealed several other factors causing the 
flap tip residues of the PR to be rigid more especially when complexed with a weaker TPV.  
This analysis also confirmed the stability of the TPV-complex as was displayed from the RMSF 
plot and distance analysis.  
The flap dynamics study highlighted several factors as being vital in determining how inhibitors 
achieve binding to the PR active site.  This study also provided deep insight into how the flap 
dynamics is affected due to binding of inhibitors differing in their binding affinities and how 
this can be used to the design of potential drugs with more potency.  This study highlighted key 
factors associated with effective binding for protease inhibitors; their good binding into the 
active site and favourable interactions with the flap region.  
In chapter three (publication 2), the stability of the dimeric form of HIV-1 C-SA PR and the 
impact of C- and N-terminal residue truncation on C-SA PR was monitored throughout 100 ns 
MD simulations.  RMSD analysis depicted a less stable pattern for the truncated systems when 
compared to the native forms of all other native systems.  The Rg analysis showed that 
truncation of C- and N-terminal residues led to less compact complex structures.  The 
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MMGBSA method displayed a reduction in binding free energies for the truncated complexed 
systems.  This is possibly due to the disruption of one of the most conserved interface regions 
(β-sheet interface) and this has been shown to have resulted in less binding affinity for the 
substrate and also the inhibitors.  
The flap tip distance analysis showed that the inhibitor bound complexes compensate for the 
loss of dimerization at the β-sheet dimer interface by ensuring that the flap tips come closer.  
The hydrogen bond interaction that occurs at the salt bridge between ARG8 of chain A and 
ASP29 of chain B or ARG8 of chain B and ASP29 of chain A was also monitored.  Truncation 
led to a collapse of this salt bridge as the truncated systems displayed less and fewer hydrogen 
bond interactions.  The outcome of this study has shown that disruption of the β-sheet dimer 
interface enables the dimerization to collapse and reduces the binding affinity of inhibitors 
designed to bind onto the active site of C-S PR.  It has also been shown that the active site 
residues displayed significant fluctuations which ultimately led to loss in binding affinity for 
active site-directed inhibitors      
  
Recommendations   
There are several lines of research arising from our study which we believe should be pursued. 
Firstly, the design of drugs which do not only have good binding into the active site of the 
HIVPR but also possess good interactions with other regions of the enzyme is a great area of 
interest for future research.  In other words, intelligent design that optimize optimum 
interactions between the inhibitor and the enzyme.    
From the results of chapter 3, a molecular modelling study is recommended that will explore a 
number of inhibitors that were experimentally shown to inhibit HIV PR dimerization.  This will 
enable the development of a suitable computational model.  It should be determined if these 
inhibitors lead to similar disruption of the β-sheet interface and subsequent interactions of the 
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rest of the PR complex.  If that is the case, new inhibitors can be proposed and tested 
theoretically, based on the results obtained.  Developing new potential inhibitors focussing on 
their interactions with the flap tips in addition to the active site region is of interest as we believe 
that when interactions of inhibitors with several regions of the protease are taken into 
considerations, potential drugs are can be developed with better potency.  We are also interested 
in exploring the significance of key residues in the dimerization interface region and how 
mutation in this region can affect the conformational stability of the HIV-1 PR.  
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Appendix 1. Supplementary material for Chapter 2  
  
  
Figure S1. Comparison of the RMSD plots of triplicate MD simulation (conformation B, C 




Figure S2. (A) Root Mean Square Deviation (RMSD) and (B) Root Mean Square Fluctuation 







Figure S3. Distance and angle analyses for the elucidation of flap dynamics in C-SA PR for 
the 60 ns MD simulations; (A) distance between flap tips (Ile50 and Ile50’), (B) distance 
between active site residue and flap tip in chain A (Asp25-Ile50), (C) distance between active 
site residue and flap tip in chain B (Asp25’-Ile50’), (D) TriCα angle of chain A (Gly49-
Ile50Gly51), (E) TriCα angle of chain B (Gly49’-Ile50’-Gly51’), (F) dihedral angles of chain 
A (Ile50-Asp25-Ile50’-Asp25’).   
  
Figure S4. Per-residue decomposition profiles of the natural substrate complex using the 





Figure S5. Cross-correlation matrices of the fluctuations of the coordinates for Cα atoms 




Figure S6: 3-D structure representing hydrogen-bond interaction of NS with certain residues 
of HIV-1 C-SA PR.  
  
  
Figure S7: 3-D structure representing hydrogen-bond interaction of ATV with certain residues 




Figure S8: 3-D structures representing (A) hydrogen-bond interaction of DRV with certain 
residues of HIV-1 C-SA PR and (B) the location of the sulfonamide group inside the complex 
system. (Note: the black star in the flap tip position denotes the removal of flap tip residues for 
illustration purposes)   
  
Figure S9: 3-D structures representing (A) hydrogen-bond interaction of TPV with certain 










Figure S10: Collective motions corresponding to PC1 obtained by performing principal 
component analysis on MD simulation trajectory after the equilibrium for DRV and LPV (the 
protein part is presented in red ribbon, higher fluctuating parts are presented in grey and blue.  
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Appendix 2. Supplementary material for Chapter 3 Supplementary materials  
  
Figure S4: Comparison of the RMSD plots of triplicate MD simulation (conformation B, C 
and D) for Apo-native with RMSD of original MD simulation (conformation A).  
  
Figure S2: Root-Mean Square Fluctuation of backbone atoms against residue number for the 




Figure S3: Root-Mean Square Fluctuation of backbone atoms against residue number for the 
APO, NS, ATV and TPV systems in Native forms.  
  
Figure S4: Root-Mean Square Fluctuation of backbone atoms against residue number for the 
APO, NS, ATV and TPV systems in Native forms.  
  
Figure S5: The plot of radius of gyration for three different systems; native, ST and DT of (A) 




Figure S6: The distance (Å) between the flap tip residues (Ile50 and Ile50') for three different 
systems; native, ST and DT of the (A) ATV  and (B) TPV complex obtained from a 100 MD 
simulation.  
Figure S7: The distance (Å) between two Gln residues from chain A and B for the three 





Figure S8: Plot of per residue decomposition energy in kcal/mol for the ATV-Native complex 
system.  
  





Figure S10: Plot of per residue decomposition energy in kcal/mol for the ATV-DT complex 
system.  
  
  
  
